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ABSTRACT 
 
Bydalek, Shawn. The Synthesis and Characterization of 2-Arachidonoyl Glycerol. 
 Unpublished Master of Science thesis, University of Northern Colorado, 2019 
 
 Cannabinoids are a structurally diverse class of compounds that act as ligands at 
the cannabinoid receptors, CB1 and CB2, through which the majority of the physiological 
effects of these compounds are mediated. Endocannabinoids (endogenous cannabinoids) 
are a subset of the cannabinoid family and include 2-arachidonoyl glycerol (2-AG) and 
N-arachidonoyl ethanolamide, and like most cannabinoids, these compounds have been 
shown to have anti-neoplastic effects on various cancer lines. The synthesis of 2-AG 
from dihydroxyacetone was selected as a research goal to try to improve yield over older 
published synthetic methods, to keep 2-AG in a protected form to avoid isomerization 
and other unwanted side reactions, and ultimately to experiment with further chemical 
modification of 2-AG and observe how this affects its anti-neoplastic activity. The 
methodology employed used the silyl ether protecting reagent t-BDPSiCl and yields up to 
the esterification step were excellent. Esterification with SOCl2 did not return yields on 
par with previous steps, but improvements in yield were seen by increasing reaction 
temperature. Analysis of deprotection was complicated by difficulties with the HPLC 
methodology, but the protecting group was found to be amenable to a single flask 
synthesis in DMF using SOCl2, which is a highly appealing quality to this methodology.   
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CHAPTER I 
INTRODUCTION 
History 
 Cannabis sativa, colloquially referred to as marijuana, is a flowering plant which 
has been utilized medicinally, ceremonially, and recreationally across various cultures 
and times (Lambert & Fowler, 2005). Inhalation of smoke from the plant or using the 
plant material in food preparation (baking) and then consuming that food leads to 
psychoactive effects, generally characterized as a sensation of euphoria and has been 
linked with various other physiological outcomes, such as stimulation of appetite or 
attenuation of short-term memory. The underlying mechanism by which these effects 
were mediated remained a mystery for over half of the twentieth century, owing primarily 
to difficulties in isolating and purifying the individual components in crude extracts. This 
changed in 1964 when Raphael Mechoulam and his research team from the Hebrew 
University in Jerusalem isolated and characterized the first psychoactive constituent        
(-)-Δ1-tetrahydrocannabinol or (-)-THC, or simply THC (see Figure 1 for the Δ1 
numbering scheme used by Mechoulam and Figure 2 for the Δ9 numbering scheme also 
commonly used by Cannabis researchers) from C. sativa (Gaoni & Mechoulam, 1964). 
The elucidation of the structure of THC reinvigorated the research involving marijuana 
and the chemical constituents of the plant, at least abroad. 
The history of marijuana use and regulation in the United States is characterized 
by turbidity. Passage of the Marihuana Tax Act in 1937 brought marijuana directly under 
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federal purview, an action that was railed against by many for its apparent intention to 
sabotage the hemp industry, in addition to its other primary purpose to act as a legal 
cudgel to prosecute specific populations of recreational users, primarily poor black 
farmers who were singled out for being "deviant." The subsequent passage of the 
Controlled Substances Act in the latter part of 1970 classified marijuana as a Schedule I 
substance, labeling it as a substance with "no currently accepted medical use and high 
potential for abuse". As a consequence of these social mores, research of marijuana in the 
U.S. languished (Peters & Nahas, 1992). 
 
 
Figure 1. Δ1 Numbering scheme for THC. 
 
Figure 2. Δ9 Numbering scheme for THC. 
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 Nonetheless, progress continued apace, although not without new challenges. The 
primary problem confronting Cannabis researchers was determining how these 
compounds were eliciting their physiological effects. Initially it was presumed that, 
owing to the hydrophobic nature of THC and other major Cannabis constituents, 
physiological activity was affected primarily through non-specific interactions with 
cellular membranes, similar to general anesthetics such as halothane (Petrocellis & Di 
Marzo, 2009). In addition, early research conducted with synthesized (+)-THC showed 
comparable activity with that of naturally occurring (-)-THC, which provided further 
evidence that bioactivity of THC was probably owed to non-specific interactions of some 
sort (Dewey, Martin, & May, 1984). However, other research conducted by Mechoulam 
indicated that the activity of THC was, in fact, enantioselective. Mechoulam's group 
published results in 1980 demonstrating that (-)-THC exhibited psychoactivity in rhesus 
monkeys at 50 µg/kg, while (+)-THC showed no activity at 1 mg/kg (Mechoulam et al., 
1980). These results strongly suggested that the physiologically active components of 
marijuana were acting at a specific receptor, or possibly some specific membrane 
element. Confirmation of this did not come until 1988, when Devane and colleagues used 
[3H]CP-55, 940 (Figure 3), a THC analogue with less hydrophobic nature, to identify a 
G-protein coupled receptor in rat brain that inhibits adenylate cyclase activity in a dose-
dependent, stereoselective manner, indicating that the receptor was of the Gi/o sub-type 
(Devane, Dysarz, Johnson, Melvin, & Howlett, 1988). 
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Figure 3. CP-55,940, a potent CB1 agonist. 
 
  The receptor was subsequently screened out of the library of orphan G-protein 
coupled receptors and designated cannabinoid receptor 1 (CB1) by Matsuda and 
colleagues (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990). The location of the 
receptor and its specificity for THC made it the leading candidate for the mediator of the 
psychoactive effects of marijuana. Later another cannabinoid receptor, dubbed CB2, was 
identified through homology cloning and was found to be surprisingly disparate from 
CB1 in its amino acid sequence, with just 44% overall sequence similarity, although this 
jumps to 68% when considering transmembrane domains only (Munro, Thomas, & Abu-
Shaar, 1993). Whereas CB1 is primarily located in the brain, CB2 was found to be located 
primarily in immune tissues (spleen, tonsils, lymph nodes, and in various leukocytes) and 
is presumed to be the key element in the immune suppressing effect of cannabinoids 
(Flygare & Sander, 2008). The identification of these receptors rationalized the 
stereospecificity of THC challenge as detailed previously, but it did not repudiate the 
possibility that non-specific interactions played some element in physiological outcomes 
for cannabinoid use, and indeed, that interaction is still presumed to play at least some 
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role in the physiological effects (Makriyannis, 1995). Furthermore, the potential cellular 
targets of cannabinoids are not exhausted by the identification of these two receptors, and 
further research has vetted several other potential cellular targets which do not bear 
further discussion at this point. In the aftermath of identification of these two receptors, 
there was an obvious question: if there is an exogeneous compound which activates a 
naturally occurring receptor, what is the endogenous counterpart? 
 An answer to this question came in 1992 when William Devane and his 
colleagues published a paper on the isolation and structure of a brain constituent that 
demonstrated activity at the cannabinoid receptors (Devane et al., 1992). The compound 
was an arachidonic acid derivative, arachidonylethanolamide (Figure 4), named 
"anandamide" by its discoverers (from the Sanskrit word "ananda" which means bliss). 
Three years later, another arachidonic acid derivative, 2-arachidonoyl glycerol (Figure 5), 
was identified almost simultaneously by Mechoulam (Mechoulam et al., 1995) and 
Sugiura (Sugiura et al., 1995) as having activity at the cannabinoid receptors. These two 
compounds constituted the first members of a new sub-class of cannabinoids, the 
endocannabinoids, and since their discovery numerous other compounds have been added 
to this sub-class (Figure 6). 
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Figure 4. Arachidonyl ethanolamide (anandamide). 
 
 
Figure 5. 2-Arachidonoyl glycerol (2-AG). 
 
 
Figure 6. Additional endocannabinoids. 
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 Identification of natural ligands for the cannabinoid receptors effectively 
canonized a new signaling system, and re-primed interest in cannabinoids and their 
pharmacological effects. One of the earliest noted, and surprisingly overlooked, of these 
effects was the concentration-dependent growth inhibition of Lewis lung adenocarcinoma 
xenografts in mice (Munson, Harris, Friedman, Dewey, & Charchman, 1975). Results 
from research conducted to examine the effects of marijuana use on intact cell and cell 
component integrity, such as a study where the prevalence of chromosome breakage in 
marijuana smoking vs. non-smoking groups was observed across a group of 60 total 
individuals (Stenchever, Kunysz, & Allen, 1974), indicated that marijuana use had 
deleterious effects on replicative elements of the cell. For instance, in the Stenchever 
study, there were approximately 2-3 times as many incidences of chromosome breakage 
in groups that smoked marijuana versus those that did not, irrespective of the amount of 
self-reported use of marijuana and the use of potentially interfering agents (caffeine, 
tobacco, etc.). In the case of the Munson experiment, treatment with 100 mg/kg of THC 
across a period of 30 days increased mean survival time for murine specimens with 
xenografts by 36% compared to controls.  The results of the Munson study were 
essentially disregarded despite their success, being succeeded by research investigating 
the palliative uses for cannabinoids (Lucas Jr. & Lazlo, 1980), which to date are the only 
therapeutic uses for which THC can be prescribed (Bifulco & Di Marzo, 2002). In light 
of the current medical landscape, this seems like either an egregious oversight or a tragic 
choice. According to the WHO's fact sheet (http://www.who.int/mediacentre/factsheets 
/fs297/en/), cancer is the second leading cause of death in the world as of 2015, and the 
probability that it will eventually become number one is extremely high, given that age is 
8 
 
 
 
a major risk factor for cancer development, and the median age of U.S. citizens has 
continued to rise steadily with time (https://www.census.gov/library/visualizations/2017 
/comm/median-age.html). 
 Regardless of the direction of research in the past, the last two decades have been 
replete with studies confirming the anti-cancer effects of cannabinoids across a wide 
variety of cancer cell types, including glioma (Salazar et al., 2009), pancreatic (Carracedo 
et al., 2006), breast (Caffarel et al., 2010), and a diverse array of other cancer types 
(Velasco, Sanchez, & Guzman, 2012). The seemingly ubiquitous effect of cannabinoids 
to impede growth, induce cell death, and inhibit invasiveness of cancer across a wide 
range of sub-types indicates an extremely promising avenue to explore for developing 
new treatment modalities for a disease which by its very nature demands treatment 
methods that balance efficacy with quality of life considerations (Cella & Cherin, 1988). 
This is a monumental task, and its difficulties are compounded by the reality that many 
standard treatment methods are non-specific and can inadvertently cause further damage, 
or even novel neoplasias themselves (Patrick, 2013). Considering these challenges, 
cannabinoids are attractive as potential treatment formulations on their own or as part of a 
comprehensive treatment package to ameliorate undesirable side effects, improve 
selectivity in treatment outcomes, and improve overall quality of life for patients. 
Statement of Difficulties and The  
Research Goal 
The process of rigorously evaluating the potential for cannabinoids to act as anti-
cancer agents requires that they be gathered or synthesized in sufficient amounts for 
further experimental use. This presents little challenge for evaluating phytocannabinoids, 
since marijuana can be grown relatively easily (acquisition of which is only limited by 
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Federal law), and the pertinent components can be extracted through simple solid phase 
extraction and then purified. The endocannabinoids present a more formidable challenge, 
as extraction from organic material is limited by the concentration present in tissue, 
typically in the nmol/g or even pmol/g range, and in some cases below the limits of 
detection (Mechoulam, Fride, & Di Marzo, 1998). Limited bioavailability could explain 
(in part at least) why the cost for 5 mg of 2-arachidonylglycerol is $300.00 from Sigma-
Aldrich as of 3/31/18 (https://www.sigmaaldrich.com/catalog/product/sigma/a8973?lang 
=en& region=US), whereas arachidonic acid (20:45,8,11,14) is concurrently priced at 
$124.00 for 250 mg (https://www.sigmaaldrich.com/catalog/product/sigma/10931?lang 
=en&region =US). 
The background information and effects of the phytocannabinoids as anti-cancer 
agents is already well established (Mechoulam & Shabat, 1999), but there are still key 
unresolved questions and avenues to explore for the endocannabinoids (as will be 
explored later in Chapter II). Due to this, the synthesis of 2-arachidonoyl glycerol was 
selected as a research goal. It seemed highly prudent to pursue a method for synthesizing 
2-arachidonyl glycerol as opposed to purchasing it directly from a manufacturer, given 
the price of arachidonic acid discussed previously. Moreover, and of primary interest, is 
the potential to modify 2-arachidonoyl glycerol in a variety of ways, from fatty acid chain 
modification or substitution, to glyceride addition, extension, or modification aimed at 
increasing overall efficacy of the modified compound, either directly or through a greater 
combined effect. Direct synthesis also affords the ability to generate 2-AG in a protected 
form, whereupon chemical de-protection or activation can generate 2-AG on demand, 
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ameliorating certain issues regarding compound availability and stability (see Chapter II 
for more information). 
Development of a synthetic method for production of 2-AG was sought for the 
aforementioned reasons. The core goal of the research was to develop a methodology at 
least as effective as previous methods in synthesizing 2-AG, with the hope of improving 
yield while concomitantly investigating permutations of 2-AG for use in activity assays. 
 
  
 
CHAPTER II 
LITERATURE REVIEW 
Overview 
 The literature review will establish important background information concerning 
the endocannabinoid signaling system (ECS). By looking more closely at this receptor 
system, it will be established how individual activation of each receptor in this system is 
directly linked to the anti-cancer activity of cannabinoid challenge, the relevant research 
data on binding of cannabinoids to these receptors, discussion of relevant structure 
activity relationship data for cannabinoids of interest for these receptors, and other 
pertinent information concerning endocannabinoids interacting with this receptor system. 
Next, relevant physiological and chemical data for 2-AG will be established, followed by 
a review of previous synthetic methodology for 2-AG culminating in the introduction of 
the synthetic methodology that will be used for this research. 
The Endocannabinoid Signaling System 
 The ECS formally consists of the two cannabinoid receptors, CB1 and CB2, their 
endogenous ligands (the endocannabinoids), and the enzymes that catalyze the formation 
and subsequent degradation of the endocannabinoids themselves (Wang & Ueda, 2009). 
The cannabinoid receptors are of the class known as G-protein coupled receptors 
(GPCRs), a family of receptors widely expressed in the body and involved in a variety of 
signaling pathways, mainly sensory perception (predominantly vision, taste, and smell) 
(Sugiura, Kishimoto, Oka, & Gokoh, 2006). GPCRs are composed of seven-member 
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alpha-helices that are interwoven in the plasma membrane and covalently linked to a 
heterotrimeric G protein located on the cytosolic side of the cellular membrane. The G 
protein subunits consist of three members, designated alpha (α), beta (β), and gamma (γ). 
The alpha subunit (Gα), which itself is a GTPase, has a bound GDP when no ligand or 
stimulus is present and constitutes the inactive form. When a ligand or stimulus hits the 
extracellular portion of the receptor, knock-on effects produce a conformational change 
in the binding pocket, causing GDP to be displaced and exchanged for GTP. This 
effectively activates the alpha subunit, which dissociates from the beta and gamma 
subunits and migrates laterally through the cellular membrane to reach and affect its 
target. The subunit's target varies based upon the type of Gα subunit and the location of 
the receptor itself (Miesfield & McEvoy, 2017). The cannabinoid receptors possess alpha 
subunits of the inhibitory type (Gαi/o), which inhibit adenylate cyclase to impede the 
downstream signaling affected by the synthesis of the secondary messenger cAMP by the 
aforementioned enzyme. Additionally, both CB receptors are positively coupled to 
mitogen activated protein kinase (MAPK) signaling pathways (Howlett et al., 2002). 
 Another effect of cannabinoid challenge at the CB receptors, and one of primary 
interest for the purpose of this research, is the de novo synthesis of ceramide as initially 
reported by Guzman and colleagues (Galve-Roperh et al., 2000). Ceramide (Figure 7), 
which is comprised of a sphingosine backbone with a fatty acid linked to the amine at   
C-2, is the biosynthetic precursor to the class of integral plasma membrane components 
known as sphingolipids, which are composed of ceramide with a C-1 linked polar head 
group. The identity of the polar head group attached to ceramide specifies the type of 
sphingolipid. In the case where the attached group is phosphorylcholine (-PO3CH-
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2CH2N
+(CH3)3), the sphingolipid is designated sphingomyelin, which is a major 
component of neural cell membranes (abundantly represented in the myelin sheath). As a 
membrane component, sphingomyelin has little to no bioactivity, but this is not the case 
with ceramide, which has been demonstrated to be integral in signaling pathways 
connected to cell survival and apoptosis (Green, 2000). 
 
 
Figure 7. Generalized structure of ceramide. 
 
 One of the primary means by which ceramide is generated in the cell is through 
the hydrolysis of sphingomyelin via sphingomyelinase into phosphorylcholine and 
ceramide. This activity has been demonstrated to be linked with CB1 activation in 
primary astrocytes and C6 glioma cells through functional coupling of the CB1 receptor 
with the factor associated with neutral sphingomyelinase action (FAN) (Guzman, Galve-
Roperh, & Sanchez, 2001). This enzyme-catalyzed generation of ceramide mediated 
through FAN occurs within minutes of cannabinoid challenge. Additionally, a second 
wave of ceramide generation occurs with prolonged cannabinoid challenge, beginning 72 
hours after treatment and peaking after 118 hours and was "closely related to the 
apoptotic death of glioma cells" (Galve-Roperh et al., 2000). This second wave of 
14 
 
 
 
ceramide production was determined to be generated through de novo synthesis of 
ceramide mediated by the enzyme pathway beginning with, and rate-limited by, serine 
palmitoyltransferase (SPT). This mechanism was determined through measurement of 
ceramide generation in the second peak time frame coupled to apoptosis of C6 glioma 
when treating the cells with THC in the presence of known inhibitors for 
sphingomyelinase and SPT. The results of this study indicated that the second wave of 
ceramide synthesis was generated by the de novo pathway mediated by SPT. 
Furthermore, the authors indicated that this activity was preserved using CB2 selective 
agonists in treating human leukemia cells via p38-MAPK activation and subsequently 
published those results (Herrera, Carracedo, Diez-Zaera, Guzman, & Velasco, 2005). The 
key take-away from this line of research is that both CB receptors are linked into 
signaling cascades that activate pro-apoptotic effects through de novo ceramide 
generation. This mode of action for the growth inhibition and apoptosis of a variety of 
cancer lines has been demonstrated across multiple independent studies, although not for 
both receptors in every case (Table 1). 
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Table 1 
Pro-apoptotic Effect of Cannabinoids on Different Cancer Lines. (Adapted from Velasco 
et al., 2012). 
Cancer cell CB 
receptor 
Ceramide 
synthesis 
Apoptosis Reference 
Glioma 1 and 2 X X Salazar et al. (2009) 
Pancreatic 2 X X Salazar et al. (2009), 
Carracedo et al. (2006) 
Hepatocellular carcinoma 2 X X Vara et al. (2011) 
Breast 2 ND X Caffarel et al. (2010) 
Rhabdomyo-sarcoma 1 ND X Oesch et al. (2009) 
Mantle Cell lymphoma 1 and 2 X X Gustafsson et al. (2006) 
Prostate 2 X X Mimeault et al. (2003), 
Olea-Herrero et al. 
(2009) 
Leukemia 2 X X Herrera et al. (2006), 
McKallip et al. (2002), 
Jia et al. (2006) 
Melanoma 2 ND X Blazquez et al. (2006) 
Lung carcinoma ND ND X Preet et al. (2008) 
X = confirmed present; ND = not determined 
 
Furthermore, several lines of evidence indicate that cannabinoid challenge is 
linked with an increase in endoplasmic reticulum (ER) stress, mediated through p8 
(NUPR1), a transcriptional regulator that affects downstream targets critical to cell 
survival, such as the Akt signaling pathway (Velasco et al., 2012). The stress response 
itself is complex and most adequately understood through the processes encompassing 
the unfolded protein response (UPR) of the ER. These processes are upregulated in 
response to cellular stressors, such as Ca2+ depletion, oxidative injury, viral infections, 
high-fat diets, hypoglycemia, the nutritional status of the cell, and certain anti-cancer 
agents (Schrӧder & Kaufman, 2005). Simply put, when the workload of the ER is 
outpaced by demand, the UPR is activated to either restore balance by increasing protein-
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folding capacity and destruction of unfolded/misfolded proteins, or if the stress cannot be 
controlled or abrogated, then Bcl-2 mediated pathways can lead to apoptosis. This is 
significant because the cannabinoid-mediated destruction of cancer cells is intimately 
linked with stress induced autophagy. The p8 mediated pathway ultimately leads to 
inhibition of the pro-survival kinase Akt (protein kinase B, also called the PKB pathway), 
which in turn inhibits the mechanistic target of rapamycin complex 1 (mTOR1), which 
then stimulates apoptosis via autophagy. Autophagy is upstream of programmed cell 
death; blocking autophagy prevents cannabinoid-induced apoptosis, but not the reverse 
(Salazar et al., 2009; Vara et al., 2011). 
 Cannabinoids also possess general anti-proliferative and anti-metastatic effects 
due to inhibition of the vascular endothelial growth factor (VEGF) pathway in addition to 
modulation of vital metalloproteases and associated inhibitory factors that are crucial for 
adhesion and invasion of transformed cells (Velasco et al., 2012). In aggregate, these 
experimental observations highlight an important feature of cannabinoids, noted 
previously, that makes their study highly intriguing but also vexing; they have a plethora 
of cellular targets, not limited to the CB receptors and not all of them pertinent or specific 
to all cannabinoids. A prime example is that of anandamide, which has been 
demonstrated to be a partial-to-full agonist of the transient receptor potential cation 
channel subfamily V member 1 (TRPV1), a "nonselective cation channel that integrates 
multiple noxious stimuli and is associated with the pathophysiology of various major 
diseases" (Ross, 2003). In simpler terms, TRPV1 is the neurological receptor that 
mediates the effects of capsaicin, the component in chili peppers that gives them their 
characteristic properties of being irritating and "hot.” 2-Arachidonoyl glycerol has no 
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activity at this receptor, nor do any other cannabinoids. It is this reality that makes trying 
to assign activities specifically to CB receptor activation sometimes confounding but 
obviously crucial when attempting to parse effects due to stimulation of the ECS. 
 Similar to all other GPCRs, the specific tissue location of the cannabinoid 
receptor dictates the ultimate physiological function(s) of its activation. Cannabinoid 
receptor distribution occurs in two primary systems: the central nervous system (CNS) 
and in immune tissues (Table 2). The first of the discovered cannabinoid receptors, CB1, 
was found to be widely distributed in the central nervous system (hence its previous 
designation as the "central" receptor) with the highest densities occurring in the cortex, 
hippocampus, basal ganglia, and cerebellum, in addition to cervical ganglia and 
peripheral autonomic nerve fibers, such as those in the bladder, heart, and vas deferens 
(Di Marzo, 1998). CB1 is also sparingly distributed in the hypothalamus and spinal cord 
and is mostly absent in the respiratory centers of the brainstem.  The distribution of CB1 
is noteworthy in the sense that, being presumed as the primary mediator of 
psychoactivity, the locations where the receptor is localized correlate with known 
physiological effects of smoking marijuana, and the absence of receptors in the 
respiratory centers may explain, in part at least, why THC and other cannabinoids have a 
low lethality (Thompson, Rosenkrantz, Schaeppi, & Braude, 1973). Curiously, although 
CB1 was initially found to be exclusive to the central nervous system, receptor transcripts 
for CB1  have been found to be expressed in immune tissue (specifically the spleen) at a 
magnitude approximately 100-fold less than CB2 (Schatz, Lee, Condie, & Kaminski, 
1997), making the initial hypothesis of a neat divide between the two receptors' domains 
murky. Across studies measuring overall receptor density, CB1 is typically found to be 
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greater than 1 pmol/mg of tissue, making it the most abundantly expressed GPCR in 
neuronal tissue and placing it on the same level as common ionotropic receptors. The 
specific localization of the receptor varies between broad, uniform expression, such as in 
the cerebellum, but in most neurons expression of CB1 is exclusive to synapses, 
specifically the pre-synaptic terminals (Howlett et al., 2002).  In addition to previously 
mentioned shared downstream targets of CB1 activation (namely adenylate cyclase and 
MAPK), cannabinoid stimulation of CB1 also affects various ion channels, through Gαi/o 
interactions, leading to activation of A-type and inwardly rectifying potassium channels 
and inhibition of N-type and P/Q-type calcium channels (Howlett, 2005). 
Table 2 
Cannabinoid Receptor General Information. (Adapted from Howlett et al., 2002). 
 CB1 CB2 
Amino acids 472 (Human) 360 (Human) 
Expression CNS, peripheral autonomic 
neurons, sparingly located 
outside CNS 
Immune tissues (spleen, 
tonsils, lymphocytes), 
expression in CNS in 
neuroinflammatory disease 
2-AG Ki range 58.3 - 472 nM 145 - 1400 nM 
Anandamide Ki range 61 - 543 nM 371 - 1940 nM 
Primary activity Neuromodulation, neural 
network development 
Immunomodulation 
 
 The distribution, overall density, and activity of the CB1 receptor hints at one of 
its primary physiological purposes, namely attenuation or modulation of 
neurotransmission (Bisogno et al., 2003). Neurotransmitter binding onto a post-synaptic 
receptor generates a response, either through ion channel opening creating a transient 
imbalance in the normal ionic content of the terminal axon or stimulation of secondary 
messenger production. This stimulates the transient production and release of 
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endocannabinoids into the synaptic cleft where they act as retrograde messengers and 
complex with CB1 resulting in the inhibition of voltage-gated Ca
2+ ion channels and 
subsequent termination of neurotransmitter release (Figure 8). Via neuroblastoma 
cultures treated with ionomycin, it has been demonstrated that endocannabinoid release is 
specifically linked to calcium influx, and the stimulation of calcium-dependent lipases 
(Bisogno et al., 1997); however, calcium independent synthetic routes mediated via 
protein kinase C and A (both in the presence and absence of thrombin) have also been 
elucidated in conjunction with sensory neuronal pathways (Vellani et al., 2008), 
demonstrating that transient neuronal endocannabinoid synthesis can be triggered by a 
number of different means. 
 
 
Figure 8. Diagram of endocannabinoid release in neurotransmission. 
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CB1 receptors are also implicated in proper neuronal network development during 
brain growth, and research has shown that diacyl glycerol lipase (a key enzyme in the 
synthesis of 2-AG) expression is required for proper axonal growth and development and 
correlates strongly with shifts in receptor expression from brain development in children 
to expression of the receptor as a signal modulator in adulthood (Bisogno et al., 2003). As 
has been discussed previously, the receptor is hypothesized to primarily mediate the 
psychotropic activity of recreational use of cannabinoids and as such is implicated in the 
regulation of cognition, memory, and motor activity as well (Sugiura et al., 2006). 
 CB2 receptor expression occurs almost exclusively in immune tissues, with the 
first identification of the CB2 receptor occurring in mouse spleen cells (Kaminski, Abood, 
Kessler, Martin, & Shatz, 1992). Autoradiographic studies have identified CB2 receptor 
expression in multiple lymphoid organs. mRNA for CB2 is found in the spleen, thymus, 
tonsils, bone marrow, pancreas, splenic macrophage/monocyte preparations, mast cells, 
peripheral blood leukocytes, and in a variety of cultured immune cells, in addition to the 
prevalence in hematopoietic lineages including myeloid, macrophage, mast, B-lymphoid, 
T-lymphoid, and erythroid cells. The density of the receptor in spleen and tonsils is on 
the same order as that of CB1 expression in the central nervous tissues (on the order of 1 
pmol/mg), but expression in human blood cell populations is tiered, following the order:                        
B lymphocytes > natural killer (NK) cells >> monocytes > polymorphonuclear 
neutrophils > T8(cytotoxic) lymphocytes > T4(helper) lymphocytes (Howlett, 2005). 
Receptor location/concentration within these various organs, tissues, and cells is not 
uniform, and the exact location within each is informative of activity but is beyond the 
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scope of this research to dissect further. CB2 is the primary mediator of the 
immunomodulatory effects of cannabinoid use and, owing to the complex and integrated 
nature of the immune response in general, a clear picture of the receptor's role in 
immunomodulation is a slowly emerging reality. For instance, CB2 activity is achieved 
via the same general pathways as CB1, i.e., through the Gαi/o inhibition of adenylate 
cyclase and stimulation of MAPKs; however, MAPK stimulation via CB2 is complicated 
by the data that, in general, endocannabinoids stimulate MAPK activity (2-AG to the full 
extent, anandamide partially), but cannibinol, a phytocannabinoid derivative of 
cannabidiol (CBD), one of the primary components of C. sativa, actually inhibits the 
ERK family of MAPKs (Paralaro, Massi, Rubino, & Monti, 2002). The specifics of how 
cannabinoids affect immune function quickly becomes difficult to parse, except for those 
with an intimate working knowledge of the immune system and could account for 
hundreds of pages of content in its own right. For the sake of comprehension, the primary 
effects of CB2 receptor activation can be rudimentarily generalized as follows. 
 First, the overall effect of CB2 receptor activation seems to be the positive 
regulation of immune function via the cAMP signaling cascade, although this is muddled 
somewhat by the fact that CB1 receptor expression does occur within immune tissues, to 
an extent 10-100 times less than CB2 receptor expression, and CB1 has been 
demonstrated to be dually linked, in some cases, to both inhibitory and stimulatory Gα 
subunits (Parolaro et al., 2002). This activity needs to be taken into account when 
drawing a formal picture of cannabinoid effect on immunomodulation and is further 
complicated by the Gα/io-dependent and Gα/io-independent stimulation of MAPKs and the 
duplicitous nature of specific cannabinoids to inhibit or stimulate those signaling 
22 
 
 
 
pathways. Regardless of the complicating factors, a generalization that can be made is 
that cannabinoid challenge has the effect of antagonizing immune cell activation, 
especially in the early stages of such activity. For instance, anandamide generally inhibits 
T and B cell proliferation, as does 2-AG, but inhibition by 2-AG appears to be critically 
dependent on overall cell density, which was attributed to a possible positive effect 
achieved through the generation of a 2-AG metabolite with immunostimulatory effects 
occurring as a result of increased metabolism at the higher cell density (Parolaro et al., 
2002). In addition, THC treatment of murine specimens has been demonstrated to cause 
direct changes in immunological profile and induce mobilization of myeloid-derived 
suppressor cells, which typically function in chronic inflammatory conditions, 
particularly those that derive from neoplastic disorders (Mantovani, 2010). Selective 
activation of the CB2 receptors has also been demonstrated to induce apoptosis of an 
array of different immune cell types, which has been proposed to be involved in the 
immunosuppressive effects of cannabinoid challenge (Parolaro et al., 2002). Given these 
data, it seems that cannabinoid challenge at CB2 could be stimulatory for tumor growth 
(and it is indeed implicated as being a culprit for that effect); however, in certain cancer 
types (pancreatic, breast, and hepatic) CB2 antagonists abrogate the anti-cancer effect of 
cannabinoid treatment, which seems to contradict the evidence that CB2 activation is 
probably harmful to the natural anti-cancer function of the immune system (Velasco et 
al., 2012). Taken in aggregate, the data surrounding the effects of CB2 receptor activation 
on immune function indicate that receptor activation leads ultimately to immune 
suppression in general, but there is also strong evidence that cannabinoid challenge elicits 
unique effects on transformed (cancerous) vs non-transformed cells (Velasco et al., 
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2012). The paradigm of immune suppression linked to CB2 activity is one that is under 
active investigation and continuous refinement, and it is vital to keep the unique 
peculiarities associated with the structurally, and in some cases functionally, diverse 
cannabinoids in mind when assessing studies concerning this topic. 
 Both CB receptors are generally found on average to be upregulated in cancerous 
tissue compared to non-cancerous tissue (see Table 3), the exact pathway by which this 
occurs being currently unknown. One interpretation of the correlation between receptor 
upregulation and malignancy might be an increased need or benefit for ECS signaling for 
uncontrolled growth, which is not exhaustive of the possibilities, but if true it might 
explain, at least in part, data that indicate activity at CB receptors is pro-tumorogenic. 
Conversely, there are data that link receptor knockout and increased expression of 
degradation enzymes of the ECS pathway (explored further later), to the development 
and progression of aggressive cancer types (Velasco et al., 2012). Fundamentally, this 
means that utilizing the ECS could result in either one of two outcomes when treating 
cancer cell populations. Either positive outcomes could occur, in this case, positive being 
cell cycle arrest or cell death, or negative, meaning accelerated growth compared to 
control or no effect. There is already a significant data pool that pairs the ECS with pro-
tumorogenic (negative) and anti-tumorogenic (positive) outcomes depending on different 
experimental conditions, primarily the specific cancer cell being studied, the 
cannabinoids being assayed, and the concentration of the cannabinoid in the experimental 
assays or growth conditions (Velasco et al., 2012). The Flygare and Sander (2008) article 
serves as an excellent introductory resource to this growing body of work (see Table 1). 
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Table 3 
CB Receptor Upregulation in Different Cancer Types. (Adapted from Flygare and 
Sander, 2008). 
Cancer sub-type CB1 CB2 
Astroglia + = 
Breast - ++ 
Mantle cell lymphoma ++ ++ 
Acute myeloid leukemia N/A ++ 
Hepatocellular carcinoma ++ ++ 
Non-melanoma skin cancer = = 
Prostate ++ ++ 
(-) partially downregulated, (=) no change, (+) partially upregulated, (++) upregulated 
 
Determining the impact of different cannabinoids at CB receptors across different 
cancer cell types has been straightforward; however, determining the effect of 
cannabinoid concentration, specifically for 2-AG and other endocannabinoids, has not.  
The first issue, which will be expounded upon later, is the inherent labile nature of the 
ester moiety in 2-AG. Whether through hydrolysis or isomerization into the 1 or 3 
position, the affinity for the receptor can be affected, if not abrogated, by these natural 
chemical transformations. In general, the highly lipophilic nature of most cannabinoids 
complicates all in vitro studies of affinity assays for receptor binding, given that the CB 
receptors are membrane bound and thus most assays must address the issue of membrane 
intercalation as a complicating factor in accurately assaying cannabinoid concentrations 
in solution across the time necessary to perform the assay. 
The high variability across various studies measuring CB receptor affinity for 2-
AG and other endocannabinoids reflects these issues. Table 2 presents Ki values, or rather 
a range of values, referenced from Howlett et al. (2002). The range is indicative of 
minima and maxima derived from various studies included in that reference. The data 
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speak for themselves; however, it is prudent to add a few pertinent background details to 
flesh out the quantitative data. In general, the literature surrounding binding assays for 2-
AG and anandamide indicate that anandamide is in fact a partial agonist for both CB1 and 
CB2 whereas 2-AG is a full agonist (Sugiura, Kobayashi, Oka, & Waku, 2002). This is a 
curious discovery, and one of the reasons 2-AG was selected for synthesis over 
anandamide for the current research. Anecdotally, when reviewing the literature, the 
general trend reported by researchers is that anandamide has a higher affinity for both CB 
receptors compared to 2-AG, however, looking at the range of binding affinity values in 
aggregate data (see Table 2), this claim is not supported. Most likely, sensitivity of assays 
to experimental conditions and the difficulties associated with assaying these compounds 
not addressed by some experimental methodologies is contributing to the disparity 
between some researchers claims and the breadth of available data. A prime example of 
this is a study measuring the binding affinity of 2-AG and anandamide at CB1 by 
Gonsiorek et al. (2000). When measuring the Ki of 2-AG and the Ki of anandamide 
against CP-55,940 (Figure 2), the reported Ki values were 949 ± 270 nM and 795 ± 46 
nM, respectively, whereas EC50 values were 38.9 ± 3.1 nM and 121 ± 29 nM, 
respectively, from the same experimental conditions (Gonsiorek et al., 2000). The results 
demonstrate clearly that 2-AG is a more potent activator of CB1 but has a lower affinity 
compared to anandamide, confusingly however, the authors claimed that both 2-AG and 
anandamide were full agonists at CB2, which runs directly counter to the consistent 
message of numerous publications from both Mechoulam and Sugiura that anandamide is 
only a partial agonist. For example, one of the first studies published concerning the 
agonist status of 2-AG at CB1 by Sugiura indicated that a response (increase in 
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intracellular Ca2+) was detected from 2-AG administration at a concentration as low as 
0.3 nM, in line with potent CB1 selective agonists, such as CP-55,940, whereas 
anandamide did not elicit a full response at any concentration (Sugiura et al., 1999). The 
disparity in results reported from multiple labs across various studies highlights the need 
for refined and continued studies of receptor interactions, at least if a highly accurate 
measure of CB receptor affinity for their natural ligands is desired. 
 A helpful development for assessing CB receptor-ligand interactions is the 
elucidation of the crystal structure of CB1, which was recently reported (Hua et al., 2016). 
The receptor was crystallized as a complex with AM6538 (Figure 9), a rimonabant 
derivative synthesized specifically for the crystallization study with high affinity for the 
receptor. 
 
Figure 9. AM6538. 
 
Additionally, to facilitate crystallization of the receptor-ligand complex, 
truncation of the CB1 receptor was required, which bears keeping in mind prior to 
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extrapolating on pertinent binding pocket elements. To facilitate discussion, it is prudent 
to parse AM6538 into three basic "arms" (Figure 10). From the pyrazole ring core, the 
arms essentially designate the three different binding pockets of CB1. The 2,4-
dichlorophenyl ring constitutes arm 1, the 4-aliphatic chain substituted phenyl ring 
constitutes arm 2, and the piperidin-1-ylcarbamoyl group constitutes arm 3. 
 
Figure 10. AM6538 "arms". 
 
It is somewhat difficult to look at AM6538 and mentally superimpose how the 
natural ligands 2-AG and anandamide interact with the pockets outlined by the arms of 
this compound. As an inverse agonist AM6538 binds CB1 in an inactive state, but the 
study authors were able to use molecular modeling software to predict how a suite of 
agonists most likely interacts with the binding pocket. Giving the simplest distillation, the 
hydrophilic head of each endocannabinoid sandwiches itself into the pocket occupying 
the space of the pyrazole core and the shallow pocket of arm 3, formed by the N-terminal 
portion of the receptor and extracellular loop 2, while the aliphatic tail of the arachidonic 
acid folds itself into a similar "C" shape as that in Figure 4 and sequesters itself into the 
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deep pocket of arm 2. Arm 1 is predominantly involved in antagonist binding and so has 
little to no interaction in agonist binding models (Hua et al., 2016). 
Structure Activity Relationship (SAR) data on anandamide shows that 
substitution of the hydroxyl head of the ethanolamide group with chlorine or fluorine 
sharply increases CB1 selectivity, by approximately 10 fold, whereas introduction of 
variation into the N-alkyl group also caused impressive gains in selectivity of a similar 
magnitude in Ki for CB1 when looking at substitution of the N-ethyl group for isopropyl 
or n-propyl, demonstrating that it is possible to modify the endogenous ligands for 
increased selectivity (Mechoulam et al., 1998). To date, no crystallographic studies have 
successfully isolated CB2, but expansive SAR studies with selective agonists have helped 
to fill in a rough picture of the binding pocket (unfortunately SARs for 2-AG interactions 
with CB receptors are scarce, but anandamide structural requirements can be loosely 
translated to 2-AG in some cases). These studies are providing critical insight into 
receptor-ligand interactions for the CB receptor class, especially as the understanding of 
nascent putative CB receptors has grown with time (Pertwee et al., 2010). 
The entirety of the preceding data demonstrates that cannabinoids in general 
represent compounds of interest for research, given their physiological effects on cancer 
cells, and establishes that there are good reasons for pursuing synthesis of 
endocannabinoids, specifically 2-AG, given the absence of accurate data for receptor 
interactions and the relative absence of information on this endocannabinoid compared to 
other endocannabinoids. More specific background information on 2-AG, the 
endocannabinoid of focus for this research, will now be discussed. 
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2-Arachidonoyl Glycerol Biosynthesis  
and Degradation 
 The biosynthesis of endocannabinoids following a stimulus occurs through 
different enzymes and intermediates depending on the endocannabinoid in question. 
Because the nature of the current thesis research is concerned with the chemical synthesis 
of 2-AG, the remainder of this chapter will focus exclusively on this endocannabinoid, 
although there are many generalizations and commonalities between the pathways for the 
synthesis of 2-AG and anandamide, one obviously being the dependence on arachidonic 
acid containing intermediates (Mechoulam et al., 1998). Figure 11 gives a template that 
will be used in describing the various ways that 2-arachidonoyl glycerol can be 
biosynthesized from a variety of precursors. Taking tissue measurements of 2-AG can be 
complicated by the collection methods employed. In the case of decapitation of murine 
specimens to measure tissue concentrations, 2-AG levels swell to 15 times their normal 
tissue concentration, normal tissue concentration being determined from flash freezing 
whole mice specimens prior to preparing tissue samples for analysis. Variation in tissue 
concentrations of 2-AG between sub-compartments of rat and mice brains are within 1.0 
to 10 nmol/g of tissue concentrations, which are roughly correlated with reported human 
values which tend to be an order of magnitude less (Sugiura et al., 2006). As will be 
discussed further, free 2-AG will be short lived in a physiological environment, but even 
more fundamentally, "free" 2-AG might be something of a misnomer. 
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Figure 11. Biosynthetic routes for 2-AG from various precursors. 
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2-AG is one of the more abundant monacylglycerols in the brain. Most 2-AG is 
produced from the hydrolysis of diacylglycerols (DAGs) containing arachidonic acid in 
the 2 position by an sn-1 selective DAG lipase (step G in Figure 11). Pre-cursors for 
DAGs come from phosphoinositides (PI) that are cleaved of their phosphate moiety by 
PI-selective phospholipase C (step E in Figure 11) or through the activity of a similar 
enzyme on phosphatidic acid (step F in Figure 11). Step C depicts the activity of 
phospholipase A1 converting a phosphoinositide to a lysophospholipid, and then in step D 
(or A) subsequent conversion of the phospholipid to 2-AG via lysophospholipase C. Step 
B demonstrates the possibility of production of 2-AG from a triglyceride precursor, 
which would be a less immediate source (Bisogno, Ligresti, & Di Marzo, 2005). Path G 
is the "on-demand" pathway for 2-AG synthesis. 
The lipopathic nature of the cannabinoids suggested potentially that their 
diffusion into the synapse was passive in nature, however, rapid removal from the 
intracellular space (whether expulsion or re-uptake and inactivation) is a necessary 
feature of a receptor-mediated process and suggested some transporter. Evidence for this 
transporter was first produced in studies examining anandamide cellular uptake and the 
fact that it was a saturable, temperature-dependent, and inhibitable process (Di Marzo et 
al., 1994). The proposed transporter was named anandamide membrane transporter 
(AMT) and was shown to potentially facilitate transport of 2-AG, along with a small host 
of additional cannabinoids (Bisogno et al., 2005). Inactivation of 2-AG is achieved 
primarily via two enzymes. The enzyme fatty acid amide hydrolase (FAAH) can cleave 
2-AG to arachidonic acid and glycerol (the two primary components from enzymatic 
hydrolysis) but is weakly effective towards this endocannabionid and ablation does not 
32 
 
 
 
lead to an increase in 2-AG concentration like it does anandamide. Rather, 
monoacylglycerol lipase (MAGL) in either membrane-bound or soluble form, is 
primarily responsible for cleaving 2-AG to arachidonic acid and glycerol and is strongly 
associated with CB1 receptor localization (Bisogno et al., 2005). 
 One of the peculiar aspects about hydrolysis of the endocannabinoids is the 
liberation of arachidonic acid, which is a polyunsaturated fatty acid that serves as the 
precursor to eicosanoids, a diverse array of biologically active compounds broadly 
involved in pain and inflammation. The full scope of effects from the localized increase 
in concentration of this fatty acid have not been fully explored, however, localized 
arachidonic acid concentrations have been shown to be capable of mediating Ca2+ 
stimulated transients, perhaps further feeding into the primary function of the compound 
in its monoglycerol state (Damron, Wagoner, Moravec, & Bond, 1993). The production 
of this physiologically diverse precursor is an effect that must be considered when 
drawing comparisons between relevant CB agonists, since most synthetic and plant-based 
cannabinoids are not metabolized using the same enzymes of the ECS system but rather 
utilize common metabolic enzymes, such as the cytochrome P450 family, to be converted 
into biologically inactive forms and excreted. This is one of the primary reasons that 
exploring the activity of endocannabionids is of interest, as their unique integration with 
existing biological "circuits" may confer to them unique capacities that would otherwise 
be absent, especially when looking at exposure of CB receptors to endocannabinoids in 
disease states where inflammatory and nociceptive processes are occurring. 
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2-Arachidonoyl Glycerol Stability 
 As noted previously, the stability of 2-AG in aqueous solutions is subject to many 
factors. Specifically, three key processes, highlighted in Figure 12, contribute to the 
progressive and nearly complete conversion or loss of 2-AG, irrespective of enzymatic 
action. Rouzer and colleagues published an experimental assessment of 2-AG stability 
looking at various pertinent parameters for experimental assays or other procedures and 
noted important upper limits for time-based procedures, as well as other important 
considerations (Rouzer, Ghebreselasie, & Marnett, 2002). In the case of oxidation and 
ester hydrolysis, the authors noted that only experiments "exceeding 4 hours" would be 
problematic for loss of function due to natural sample loss. However, acyl migration 
could occur at rates that "would be significant in the context of experimental protocols of 
an hour or less." Further elaboration of what was meant concerning this revealed that 
migration of the acyl chain to the first or third position on the glycerol molecule is a 
thermodynamically favored migration, and so at equilibrium the 1(3)-monoglycerol will 
constitute 89 to 95% of the monoglycerol present (Rouzer et al., 2002). The speed of this 
process was critically dependent on the presence or absence of serum. In the presence of 
serum, the half-life for the conversion of 2-AG to 1(3)-AG was approximately 2.3 min, 
and in the absence of serum the same reaction half-life was 10 min. Study authors 
postulated that this might be due to the presence of albumin in serum and verified that 
albumin binding was responsible for the increased rate in conversion. The consequences 
of these data for developing experimental methods is obvious, as is the implication in 
potentially using the compound in formulations. One further finding that was perplexing 
was the steady loss of 2-AG due to processes unknown. It was determined that 2-AG will 
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actually bind non-selectively to glass surfaces, and natural loss to glass containers (on the 
order of 10% of total sample lost per hour) was to be expected (Rouzer et al., 2002).  
 
 
Figure 12. 2-AG physiological transformations. 
 
The pertinent results from Rouzer et al. (2002) are summarized in Table 4. These 
instabilities in 2-AG in a natural cellular environment are major contributors in the dearth 
of consensus in the published information concerning this compound, therefore, 
developing knowledge of the chemical susceptibility of 2-AG will greatly help to inform 
the discussion concerning synthetic strategy moving forward. 
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Table 4 
Sources of 2-AG Loss. (Adapted from Rouzer et al., 2002). 
Source/condition  Measure of loss  
Oxidation  Stable up to 6 hrs at 37 °C  
Hydrolysis  Stable up to 6 hrs at 37 °C  
Acyl migration  In buffer (pH 7.4): t1/2 = 10 min 
In buffer (pH 7.4) with 10% FBS: t1/2 = 2 min 
Base catalyzed (kcat = 78,000 M/min)  
Loss to glass/plastic 
surface adsorption  
Approximately 10% loss/hr  
 
Synthetic Pathway Proposal and Review of  
Previous Methodology 
 Previous publications concerning 2-AG synthesis are fairly sparse. Han and 
Razdan (1999) employed the Corey method for forming silyl ethers, using 
triisopropylsilyl chloride to protect glycerol. The authors esterified their protected 
glycerol to an activated arachidonic acid using 4-dimethylaminopyridine (DMAP), 1-(3-
dimethyl-aminopropyl)-3ethylcarbodiimide hydrochloride (EDCI), and dichloromethane 
at ambient temperature. Subsequent deprotection was achieved using a modified tert-
butylammonium fluoride (TBAF) process employing an acetate buffer kept at -20 °C over 
night. The reported yield for 2-AG was 59%. The need to bring reaction conditions to 
lower overall temperatures is a common theme reported in publications. For instance, the 
method employed by Suhara and colleagues sought to create a 1,3-dioxane ether complex 
through glycerol that could be selectively cleaved to form the 2-monoglycerol on 
demand. The methodology was inspiring, and the yield was improved, but still 
underwhelming, peaking at 69% (Suhara et al., 2000). A more recent publication from 
Cartoni et al. (2004) critiqued what was seen as the established sensible synthetic route 
(Figure 13). The appeal of their method comes from having pared the number of 
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individual synthetic steps down to two, by addition of a pre-protected glycerol in the 
form of 1,3-dibenzyloxy-2-propanol, and then subsequently deprotecting. The 
deprotection was screened with various reaction conditions, but the best method only 
yielded a 70% recovery (with returns as low as 30%) after deprotection (Cartoni, 
Margonelli, Angelini, Finazzi-Agro, & Maccarrone, 2004). Given these outcomes, older 
methodologies are still clearly viable, and it is from the principle scheme in Figure 13 
that the synthetic route for the current research was drawn. 
 
 
Figure 13. Classic synthetic scheme for 2-AG. 
 
The Han synthetic method, which was essentially a retooling of a method 
developed by E. J. Corey in 1972 (Corey and Venkateswarlu, 1972) was sound, but 
impeded by issues with the chosen protecting group. Silyl ethers are susceptible to attack 
by the extremely basic fluoride anion and an acetate buffer was employed, presumably, to 
ameliorate formation of 1(3)-AG by keeping pH < 7. The trade-off for stabilization of the 
product on the overall reaction kinetics appears to be manageable (assuming overnight in 
the Han methodology does not constitute a time period over eight hours) and if the 
protecting group were more, or at least as, labile, it seems that it should be possible to 
tweak the deprotection conditions and return a better result. With that in mind, tert-
butyldiphenylsilyl chloride was chosen to form a silyl ether protecting group for the 
synthesis of 2-AG. 
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  Figure 14 gives a simplified outline of the proposed synthetic scheme for 2-
arachidonoyl glycerol for the current research. The initial proposed synthetic method 
employed dihydroxyacetone (DHA) as a way to ensure protection specificity, and so 
added additional steps that made the use of DHA less appealing as a starting material 
once it was realized that the protecting group was specific for primary alcohols by a wide 
margin in the original reaction conditions (Patschinski, Zhang, & Zipse, 2014); however, 
as will be elaborated later, it was found that the doubly protected DHA could be 
conveniently separated from DMF called for in the original Corey procedure. DMF is 
unfortunately one of the few polar, aprotic solvents that can dissolve all the necessary 
reagents for the synthetic procedure in required amounts, and efficient and clean removal 
of the solvent can be a beneficial step to include if thinking of scale up. 
 
 
Figure 14. Simplified synthetic scheme flow chart. 
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 Based upon the breadth of data discussed thus far, the reasons for pursuing this 
research should be readily apparent. Cannabinoids are compounds with demonstrated 
anti-cancer effects on a variety of cancer sub-types that act upon a unique class of 
receptors, and there is potential in developing and building upon previous synthetic 
methodologies to allow further experimentation with these compounds to fully probe 
their efficacious properties and potential. 2-AG in particular is a target of imminent 
interest for synthesis due to the relatively unexplored potential of the endocannabinoids 
as therapeutic agents compared to the other cannabinoids, and the relatively mixed data 
on the compound as a whole. 
 
  
 
CHAPTER III 
MATERIALS & METHODS 
Materials 
 Materials were primarily acquired from Sigma-Aldrich and American Type 
Culture Collection (ATCC). Reagent grade (purity ≥ 95%) dihydroxyacetone (DHA) 
(D107204), tert-butyldiphenylsilyl chloride (t-BDPSCl) (190502), imidazole (I5513), 
dimethyl formamide (DMF) (PHR1553), acetone (650501), acetonitrile (271004), 
dichloromethane (DX0831), chloroform-d (494275), chloroform (CX1054), methanol 
(34860), denatured ethanol (187380), ethanol (absolute and reagent grade) (E7023 and 
362808), thionyl chloride (230464), and methyl chloroformate (M35304) were obtained 
from Sigma-Aldrich. Glycerol was provided by the laboratory stock room. From ATCC, 
AsPC-1 (pancreatic cells CRL-1682), U-87 MG (neuroblastoma cells HTB-14), RPMI-
1620 medium (30-2001), Eagle's Minimum Essential Medium (EMEM) (30-2003),      
25-cm2 culturing flasks , 75-cm2 culturing flasks, 1-mL serological pipettes, 5-mL 
serological pipettes, 25-mL serological pipettes, 5-mL conical centrifuge tubes, 15-mL 
conical centrifuge tubes, and 25-mL conical centrifuge tubes were obtained. All other 
culturing materials were kindly provided by Dr. Steve Mackessy's laboratory, including 
dimethyl sulfoxide (DMSO) and fetal bovine serum (FBS) both from ATCC. EMD 
Millipore TLC Silica Gel 60, F254, aluminum backed thin layer chromatography plates 
(1.10557.0001) were purchased from Fisher Scientific. 
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Instrumentation 
 A Bruker 400 MHz nuclear magnetic resonance spectrometer was utilized for 
monitoring reaction success and characterization of purified product. A Nicolet iS5 
infrared spectrometer with an iD5 ATR cell from Thermo Scientific was used to analyze 
starting materials and products. A Shimadzu HPLC system consisting of a LC-10AD 
pump, an SPD 10A UV/Vis detector, and outfitted with a Luna Omega Polar C18 column 
(4.6 mm x 150 mm; silica particle size 1.6 µm) was utilized for determining purity and 
monitoring protecting group removal. A Labconco lyophilizer was utilized for conversion 
of DHA dimer into monomer. 
Nomenclature and Abbreviations 
 Before moving forward, it is pertinent to take a moment to discuss annotation of 
the intermediates in the synthetic scheme. From this point, the author's own personal 
shorthand will take the place of formal/IUPAC names for these intermediates, and this is 
primarily because these formal terms are cumbersome. Figures 15, 16, and 17 give the 
structure, IUPAC name, and the author’s abbreviation for each compound. This naming 
system will be maintained throughout the paper. 
 
 
Figure 15. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-propanone - DHA-DS 
(doubly silylated). 
42 
 
 
 
 
Figure 16. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-hydroxypropane - G-1,3-DS. 
 
 
Figure 17. 1,3-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-propanoyl-(5Z, 8Z, 11Z, 
14Z)-eicosatetraenoate - 2-AG-DS. 
 
Synthetic Methodology 
Step 1 - Monomerization of  
Dihydroxyacetone  
The overall synthesis of 2-AG was carried out on the milligram scale, but for the 
purpose of conversion of DHA dimer into monomer (Figure 18) for use as a starting 
material, amounts ranging from 1 to 3 grams were used. To aid in the quick recovery of 
the monomer, the minimum amount of deionized (DI) water to dissolve the DHA crystals 
was used in every case, which involved adding ~0.5 mL aliquots of DI water until a 
concentrated solution was formed. The concentrated solution was stirred for one hour 
before it was transferred into a Labconco freeze drying flask and frozen with uniform 
distribution in the flask using liquid nitrogen. Then, the flask was attached to the 
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Labconco lyophilizer and brought to dryness at approximately 0.050 mBar at 0 °C. Due 
to the hydrophilic nature of DHA, multiple cycles of freeze drying were often required to 
bring to full dryness. In some cases, it was necessary to triturate the semi-solid product 
with very minute aliquots of absolute ethanol and vigorously whisk the resultant paste 
until dry crystals were returned. Distributing a semi-hydrated sample onto a large watch 
glass and passing nitrogen gas across the surface combined with mechanical perturbation 
was also helpful in bringing a sample to complete dryness. In some cases, samples that 
proved particularly difficult were placed in the fume hood over night to dry from the 
laminar air flow in the hood. Successful monomerization was determined by melting 
point analysis; the monomer has a melting point range of 89 - 91 °C, and the dimer melts 
between 75 - 80 °C. Stored in a sealed container and placed in a desiccator, the monomer 
will slowly convert to dimer over a period of several months (Davis, 1973). 
 
 
Figure 18. Monomerization of DHA. 
 
Step 2 - Protection of  
Dihydroxyacetone 
 Figure 19 gives an overview of the first synthetic step: addition of the protecting 
group. To a 25-mL round-bottom flask was added 100 mg (1.1 mmol) of monomerized 
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DHA and 10 mL of DMF. A stir bar was then added, and the flask contents were mixed 
gently until homogeneity. Then 151 to 226 mg (2-3 molar equivalents) of imidazole were 
added, followed with 693 µL (1.1 molar equivalents) of t-BDPSiCl. The reaction stirred 
for 30 min after which it was quenched with 10 mL of deionized water. The round-
bottom flask was covered with aluminum foil and placed in a 0 °C freezer, causing 
precipitation of the doubly silylated (protected) DHA (DHA-DS). When using less DMF, 
typically ≤ 5 mL, and using the same amount of DHA, the product typically precipitates 
out of solution without needing to be cooled. 
 
 
Figure 19. Protection of DHA with t-BDPSiCl. 
 
The contents of the round-bottom flask were then transferred to a Buchner funnel 
and washed with 5-mL aliquots of 0 °C deionized water while simultaneously being 
ground and physically manipulated with a glass stir rod. After washing approximately 3-5 
times, the crystals were carefully transferred to a pre-weighed watch glass, dried at 
ambient temperature, and weighed again for recovery determination. The crystals were 
stored in a screw-cap vial at 4 °C until the next step. Reaction success was monitored 
using infrared spectroscopy, looking specifically for the disappearance of the diagnostic 
alcohol band at 3400 cm-1. Absence of this band indicated complete double protection of 
the compound, which was further verified using 1H NMR.  
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Step 3 - Reduction of DHA-1,3-DS 
 Figure 20 shows the next step in the synthesis: reduction of DHA-DS to G-1,3-
DS. From the product isolated and purified in step 2, 100 mg (0.18 mmol) were added to 
a 50-mL round-bottom flask containing 5 mL of tert-butanol. The flask was placed in an 
ice bath, and the contents were stirred gently while 8 mg (1.2 mol equivalents) of sodium 
borohydride (NaBH4) dissolved in 5 mL of basic (pH > 9) t-butanol solution was added 
drop wise over 15 min. The contents were stirred for an additional 105 min, and the 
reaction was quenched with 1.0 M HCl to a pH of ~7, upon which the clear reaction 
mixture became slightly opaque. The solution was dried at 50 °C for 30 min to remove 
the t-butanol, and the mixture was back-extracted with 5-mL aliquots of chloroform three 
times. The aliquots were combined and concentrated by drying at ambient temperature on 
a pre-massed watch glass and to determine recovery. 1H-NMR spectra were gathered to 
determine reaction success. 
 
 
Figure 20. Reduction of DHA-DS to G-1,3-DS. 
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Step 4 – Esterification 
 Figure 21 gives the outline of the next synthetic step: esterification of G-1,3-DS 
with 2-AG to form 2-AG-DS. From product isolated and purified in step 3, 100 mg (0.2 
mmol) was added to 5 mL of chloroform along with 12 mg (one molar equivalent) of 
imidazole in a 25-mL round-bottom flask. The flask was placed in an ice bath and stirred 
at a gentle rate, and 100 mg (0.3 mmol) of arachidonic acid was added. To the flask, 5 
mL of chilled chloroform containing 70 µL (1.1 molar equivalents) of SOCl2 were added 
to the stirred contents of the round-bottom flask slowly over 30 min. The reaction was 
stirred for another 2.5 hr before being quenched with approximately 1 mL of deionized 
water. The flask contents were dried at 40 °C and filtered over anhydrous magnesium 
sulfate. 
 
 
Figure 21. Esterification of G-1,3-DS with 2-AG utilizing SOCl2. 
 
The gelatinous product was then reconstituted in 5 mL of pentane and washed 
three times with 5 mL of pH ≈ 9-10 aqueous NaOH. The organic layer was filtered 
through MgSO4 and then added to a clean 25-mL round-bottom flask. The round-bottom 
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flask was fitted with a rubber septum which was ventilated via a syringe needle and 
connected via another syringe needle to a nitrogen tank. The flask was flushed with 
nitrogen gas for approximately 5 min. The flask was then sealed and stored at 4 °C. 
During the reaction, small aliquots were removed for 1H-NMR analysis to determine 
successful esterification. 
Step 5 - Protecting group removal 
 Figure 22 gives the generalized reaction for the deprotection step of 2-AG-DS; 
multiple methods were utilized in deprotection attempts. Table 5 outlines the five primary 
removal methods employed. The removal conditions are amalgamations or permutations 
of removal methods employed by Han and Razdan (1999), Nicolaou and Webber (1986), 
and Corey's own original deprotection method utilizing tetra-n-butyl ammonium fluoride, 
TBAF (Corey and Venkateswarlu, 1972). 
 
 
Figure 22. Deprotection of 2-AG-DS. 
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Table 5 
Protecting Group Removal Conditions. 
Method  Removal Agent (all in THF)  Temperature range 
(°C) 
Time (hr.) 
A  6 mol eq. of TBAF  0 °C 8 hr. 
B 6 mol eq. of TBAF 
1 mol eq. imidazole  
0 °C 8 hr. 
C  6 mol eq. of TBAF 
3 mol eq. of AcOH  
0 °C 8 hr. 
D  6 mol eq. of TBAF 
6 mol eq. of AcOH  
-20 to 0 °C 24 hr. 
E  10:1 HF/pyridine  -20 to 0 °C 24 hr. 
 
Deprotection was carried out under inert conditions; in each case reagents were 
added to a 25-mL round-bottom flask sealed with a rubber septum and flushed with 
nitrogen gas. Each reaction was performed with 100 mg (0.117 mmol) of 2-AG-DS, with 
the additional reagents matching the molar equivalents given in Table 5, in 5 mL of THF. 
The initial three removal methods, A, B, and C, were performed for 8 hr, after which 1 
mL of concentrated aqueous MgCl2 was added to the flask and the flask was gently 
shaken by hand for 1-2 min to precipitate any free fluoride ion. The solution was then 
vacuum filtered to remove the precipitate and subsequently transferred into a clean 50-
mL round-bottom flask and dried under reduced pressure at 40 °C. The flask contents 
were reconstituted in 5 mL of chloroform and extracted with three 5-mL aliquots of pH 
9-10 aqueous NaOH. The aqueous layers were transferred to a new flask, dried again at 
40 °C, and the residual product was reconstituted in CDCl3 and 1H-NMR spectra were 
taken to determine identity.  
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Difficulties with the initial deprotection methods prompted a change in 
methodology. For removal methods D and E, reaction time was increased to 24 hr and 
each method was analyzed via HPLC. For an initial eight hours, the reaction mixture was 
stirred at 0 °C and sampled at 3 hr by drawing 0.5 mL of the reaction mixture into a 
syringe and transferring into an Eppendorf tube, followed subsequently with 
approximately 100 mg of MgCl2 to precipitate any free fluoride ion. The solution was 
then filtered into a new Eppendorf tube and adjusted to a pH of approximately 3 (verified 
by spotting on pH paper) with a 1.0 M NaOH solution and was stored in a -20 °C freezer 
until analysis. After stirring for 8 hr at 0 °C, the reaction flask was transferred to a -20 °C 
freezer for another 15 hr, to mimic the deprotection conditions upon which these methods 
were modelled. After 15 hr at -20 °C, the flask was removed, and stirred at ambient 
temperature for another hour before a final 0.5 mL sample was taken at 24 hr, quenched 
with 100 mg MgCl2, filtered into an Eppendorf tube, and placed in a -20 °C freezer until 
analysis. 
 Samples from D and E were analyzed in sequence for their t-BDPSiF 
concentration using high performance liquid chromatography, utilizing a Phenomenex 
Luna Omega Polar C18 column and a gradient solvent system starting at 30:70 
water/acetonitrile, increasing to 100% acetonitrile over 10 min, holding at 100% 
acetonitrile for 10 additional min, and then reverting to the original 30:70 
water:acetonitrile over 5 min (Rouzer et al., 2002). Flow rate was set to 1.0 mL/min and 
the UV/Vis detector was set to dual channel mode, detecting at 220 and 274 nm 
simultaneously. Aliquots of samples (20 µL) at each time point from each method were 
analyzed and chromatograms for each sample were collected. Deprotection success was 
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determined by calculating the concentration of t-BDPSiF, the primary by-product of 
deprotection which absorbs at 274 nm (Figure 23). Relevant data are discussed in Chapter 
IV. 
 
Figure 23. Production of t-BDPSiF during deprotection step. 
 
 The concentration of t-BDPSiF from each sample set was calculated from a 
standard curve using t-BDPSiF generated by incubating 109 mg of t-BDPSiCl with 250 
mg of TBAF in 1 mL of THF for 24 hrs. After which, the solution was quenched with 
100 mg of MgCl2 and vacuum filtered. The filtrate was recovered and used as a stock to 
prepare a series of increasingly dilute standard solutions which were analyzed using the 
previously discussed HPLC methodology. 
 The concentration of t-BDPSiF recovered from deprotection in each sample 
(determined from the generated standard curve) was converted into moles and then that 
value was divided by the total number of moles of sample available to determine total 
deprotection, which was then converted into percent deprotection (see Chapter IV for a 
sample calculation). 
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Cytotoxicity Assay 
 In anticipation of successful synthesis and isolation of 2-AG, and in the interest of 
further project development, methods to screen cytotoxicity of 2-AG against various 
cancer lines were investigated and developed simultaneously with synthetic method 
development. At the recommendation of collaborators in the School of Biological 
Sciences, the MTT assay was selected for screening drug action against cellular 
proliferation (Berridge, Herst, & Tan, 2005). The MTT assay is a colorimetric assay for 
measuring cellular metabolism via the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to its insoluble formazan, (E,Z)-5-(4,5-
dimethylthiazol-2-yl)-1,3-diphenylformazan, catalyzed by mitochondrial NADPH-
dependent reductases (Figure 24). 
 
 
Figure 24. Reduction of MTT to its formazan via mitochondrial reductases. 
 
 Utilizing the MTT assay, it is possible to determine proliferation of cells treated 
with different cannabinoids at different concentrations versus controls by measuring the 
presence of the formazan product (brought into solution with the nonionic poly-
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oxyethylene surfactant NP-40). Healthy, intact cells will metabolize MTT to formazan, 
while cells that are in apoptotic or autophagic pathways (or that are simply dead) will not, 
giving a simple and effective method for measuring reactivity to cannabinoid treatment 
by measuring colorimetric response of the control wells and comparing to the treatment 
wells. Greater absorbance of sample versus control indicates proliferation, while less 
indicates death/autophagy. A sample assay protocol is given below, written specifically 
for the pancreatic cancer cell line CRL-1682. The only variation in this methodology 
from cell line to cell line would be the media employed. 
Assay Procedure 
 Pancreatic cancer cells from ATCC (CRL-1682: https://www.atcc.org/ 
products/all/CRL-1682.aspx), an adherent cell type, were plated into a 25-cm2 Corning 
culture flask with approximately 11 mL of RPMI 1640 media (https://www.atcc.org 
/Products/All/30-2001.aspx) with 10% fetal bovine serum (FBS) (https://www.atcc.org 
/products/all/30-2020.aspx) (subsequently referred to simply as media). Cells were 
incubated for 24 hr and were subsequently trypsinized using 3 mL of a 0.25% 
trypsin/0.53 mM EDTA solution (https://www.atcc.org/products/all/30-2101.aspx) and 
passed into a 75-cm2 Corning culture flask with 25 mL of media. The cells were then 
cultured for an additional 48 hr, with media refreshed every 24 hr, until the flask was 
confluent (70 to 80% cell density). The cells were then trypsinized and counted in 
triplicate using a hemacytometer, with the average of the three cell counts being used to 
determine overall cell density. 
Cells were then plated at the following cell density given in Table 6. The plate 
was incubated for 24 hr allowing cells to settle and adhere to the wells. Finally, the wells 
53 
 
 
 
were refreshed with media and the appropriate wells were treated with the cannabinoid 
that was being screened. Treatment involved addition of 1 µL of a prepared stock 
solution of the cannabinoid in absolute ethanol (one of the few amenable vehicles for 
cannabinoids). Ethanol is a common disinfectant, owing to its ability to intercalate into 
cell membranes causing lysis and subsequent death, which is why well treatment was 
kept to a single microliter of cannabinoid in vehicle (Tapani, Taavitsainen, Lindros, 
Vehmas, & Lehtonen, 1996) and readings were corrected in reference to control well 
outcomes. The cellular stock solution concentration was varied to enable screening across 
concentrations of interest and was usually in the range of 100 µM to 1 mM. Several 
methods of serial dilution were available for generating treatment wells. The first 
involved preparing increasingly dilute stock solutions of cannabinoid in ethanol and 
treating each well directly, adding 1 µL of control and filling with 99 µL of media to 
bring to a final volume of 100 µL. This method allowed for easy dilutions by a factor of 
ten but was time consuming. Another method, requiring more experience handling cell 
culture and multi-channel pipettes, was to refresh all the treatment wells with 100 µL of 
media and then prepare treatment wells in row A at 200 µL total volume at the desired 
concentration. Then, using a multi-channel pipette, 100 µL from each treatment well in 
row A were transferred to the corresponding well in row B and mixed with the multi-
channel pipette, diluting the original stock concentration by half instead of an order of 
magnitude. This process was repeated across each well (refreshing tips in between 
treatments) until finished. Each plate also contained three additional categories of wells 
in addition to treatment wells. First, two series of control wells plated at the same cell 
density and treated with an identical amount of total ethanol content as the treatment 
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wells were prepared to serve as a baseline for treatment efficacy, and absorbance from 
these wells was used to correct absorbance from other treatment wells by simple 
subtraction of the control absorbance from the treatment absorbance. Second, a blank 
series was prepared on each plate to correct background absorbance from media and 
vehicle. Finally, a series of wells plated at different cell densities were prepared on each 
plate to serve as a standard curve for determining end point cell density for the treatment 
wells (Table 6). After refreshing the media, the cells were incubated for 24 hr. Then, 10 
uL of MTT reagent were added to each well. The cells were incubated for another 24 hr. 
After this, the wells were treated with 10 µL of NP-40, placed in the dark for 4 hr, and 
then absorbance in each well was read at 570 nm using a plate reader. 
Table 6 
Cell Density for MTT Assay (in cells/mL). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 
B 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 
C 1000 1000 1000 1000 1000 1000 0 0 0 0 0 0 
D 1000 1000 1000 1000 1000 1000       
E 1000 1000 1000 1000 1000 1000       
F 1000 1000 1000 1000 1000 1000       
G 50000 50000 50000 50000 25000 25000 25000 25000 10000 10000 10000 10000 
H 5000 5000 5000 5000 1000 1000 1000 1000 500 500 500 500 
[Rows] – (Columns) – Contents; [A-F] – (1-6) – Treatment wells; [A-B] – (7-12) – 
Control wells; [C] – (7-12) – Blank wells; [G-H] – (1-12) – Standard curve wells; [D-F] – 
(7-12) – Empty  
  
 
CHAPTER IV 
RESULTS & DISCUSSION 
Conversion of Dihydroxyacetone  
Dimer to Monomer 
 Table 7 gives the percent recovery for DHA (dihydroxyacetone) dimer conversion 
into monomer. The primary issue complicating the process of recovery was the tendency 
for DHA to cling to glassware, and it is for this reason that conversion was carried out in 
400-mL beakers as opposed to round-bottom flasks. Getting full recovery often required 
meticulous scraping of glassware with a spatula and the narrow necks of round-bottom 
flasks unnecessarily complicated this process. Successful conversion was determined by 
melting point analysis as discussed in Chapter III. 
Table 7 
Percent Recovery for Conversion of DHA Dimer to DHA Monomer. 
Sample Mass (g) Recovered Mass (g) Percent Recovery Trituration (Y/N) 
1.020 0.857 84.0% Y 
1.017 0.942 92.6% Y 
0.504 0.456 90.5% Y 
1.090 0.989 90.7% Y 
3.215 3.214 99.9% N 
5.045 4.884 96.8% Y 
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Silylation of Dihydroxyacetone  
to Form DHA-DS 
 Prior to collecting 1H-NMR spectra, reaction progress and product purity were 
assessed through qualitative thin layer chromatography (TLC). Several solvent systems 
were tested for their usefulness in this regard. The most useful proved to be a denatured 
ethanol solution (91.85% ethyl alcohol, 5% methyl alcohol, 1% ethyl acetate, 1% methyl 
isobutyl ketone, 1% hydrocarbons, and 0.15% water) both for developing plates and for 
dissolving starting materials and products. Spotting sample aliquots straight from the 
reaction flask and detecting spots on a plate with iodine resulted in diffuse, amorphous 
streaking across the silica. This was discovered to be a consequence of the DMF 
interacting with the silica; the problem was resolved by diluting approximately 10-20 µL 
of the aliquot from the reaction mixture in half a milliliter of denatured ethanol before 
applying to the plate. This greatly improved spot resolution. 
 Figure 25 shows the 1H-NMR spectrum of purified crystals of DHA-DS in 
CDCl3. Clearly visible in the spectrum are the signals from DMF (Figure 26), singlets at 
2.980, 2.911, and 8.051 ppm (faintly visible upfield of the aromatic signals). Attempts 
were made to thoroughly purify the product, as described in Chapter III, but no amount of 
washing was successful in eliminating the DMF signals from any 1H-NMR spectra of the 
DHA-DS samples. Application of heat to evaporate the excess DMF was not helpful 
either, as DMF is potently non-volatile (boiling point of 153 °C), and product browning 
occurred at temperatures above 80 °C. 
Based upon the structure of DHA-DS (Figure 15), the expected 1H-NMR 
spectrum should produce a singlet in the methyl region (approximately 0-1 ppm) from the 
methyl groups on the protecting group, which when doubly protected should be 
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equivalent, a singlet from the equivalent methylene groups adjacent to oxygen at 
approximately 3-5 ppm, and signals from the aromatic hydrogens from the phenyl groups 
at approximately 7-8 ppm. These signals are clearly present in Figure 25. Full double 
protection was also corroborated by IR spectroscopy, specifically by monitoring for the 
absence of the diagnostic alcohol band that occurs from approximately 3400 to 3600 cm-1 
(Figure 27). Table 8 gives the percent recovery for reactions conducted to determine yield 
for this step, along with the average recovery for these reactions and the standard 
deviation among them. 
 
 
Figure 25. 1H-NMR spectrum of DHA-DS in CDCl3. 
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Figure 26. 1H-NMR spectrum of DMF in CDCl3. 
 
 
Figure 27. IR spectrum of DHA-DS. 
  
59 
 
 
 
Table 8 
Percent Recovery of DHA-DS. 
DHA-DS recovered (g) Percent Recovery 
0.604 92.2% 
0.625 97.0% 
0.599 94.8% 
0.587 92.4% 
0.668 98.7% 
Average 95 ± 3% 
 
Reduction of DHA-DS and Recovery  
of G-1,3-DS 
 Reduction of DHA-DS to G-1,3-DS was accomplished through the well-known 
reducing agent, sodium borohydride (NaBH4). The solvent for the reaction was t-butanol, 
selected after searching for methods that might offer an insight into which solvent would 
be best suited for using NaBH4 (Lecher, 2007). In experimenting with other solvent 
systems, ethanol and chloroform were found to be suitable substitutions as well. Percent 
recovery for reactions are recorded in Table 9. The reduction of the carbonyl of DHA-DS 
into an alcohol changes the physical state of the product from solid to a viscous liquid. 
Table 9 
Percent Recovery of G-1,3-DS 
Reaction Solvent Percent Yield 
t-butanol 95.7% 
t-butanol 97.1% 
t-butanol 91.5% 
Chloroform 99.7% 
Ethanol 96.8% 
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Use of Glycerol as a Starting Material 
 As mentioned previously in Chapter II, DHA was selected as a starting material to 
ensure protection specificity for the 1 and 3 positions for glycerol (after DHA-DS was 
reduced with NaBH4) but this was found to not be a necessary step, as the introduction of 
the silyl ether using the original protection conditions employed in the Corey procedure 
were selective for primary alcohols (Patchinski et al., 2014). Step 1 (Figure 14) shows 
how using glycerol as a starting material to produce G-1,3-DS circumvents the need to 
monomerize and reduce DHA, which makes using glycerol as a starting material 
appealing. The ease of isolation of DHA-DS from DMF was the primary reason it was 
continued to be utilized as a starting material, as it was hoped that the DHA-DS crystals 
would be easier to purify of residual DMF rather than the viscous and difficult to handle 
liquid that G-1,3-DS is, however, further work with the synthetic method, discussed later 
in this chapter, will highlight how this might not even be necessary. 
 For the sake of verification of this step, a stock of glycerol was acquired from the 
university chemical stock room, and sample trials were conducted to produce G-1,3-DS 
from glycerol. Reaction conditions were identical to those from the original procedure to 
produce DHA-DS from DHA. Approximately 100 mg (1.1 mmol) of glycerol were 
measured directly into a 50-mL round-bottom flask by dipping a clean spatula into the 
glycerol and allowing the glycerol to drip off the spatula tip into the 50-mL round-bottom 
flask resting in a 150-mL beaker, all of which were pre-tared. The glycerol was dissolved 
in 5 mL of DMF, to which 225 mg (two molar equivalents) of imidazole were added. The 
reaction mixture was stirred at ambient temperature and 700 µL (1.1 molar equivalents) 
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of t-BDPSiCl were added. The reaction mixture was stirred for 30-60 min and then the 
flask was sealed and wrapped in aluminum foil and placed in a 4 °C refrigerator. 
 Recovery of G-1,3-DS was difficult, but fortunately when the reaction flask was 
cooled, G-1,3-DS separated from DMF, and settled as a solidified gel at the bottom of the 
reaction flask. The DMF was carefully decanted from the G-1,3-DS, and the product was 
scraped onto a watch glass and dried under nitrogen gas. G-1,3-DS itself is water soluble, 
as attempts to purify with chilled 1 mL aliquots of deionized water demonstrated, and so 
the convenient method of washing DHA-DS was not amenable with G-1,3-DS. Percent 
recovery for this process was not determined, but 1H-NMR data to verify protection 
success was gathered by adding approximately 10-20 mg of G-1,3-DS to 1 mL of CDCl3 
and analyzing. 
G-1,3-DS 1H-NMR Analysis 
Figures 28 and 29 display 1H-NMR spectra of samples of G-1,3-DS isolated from 
different syntheses employing the two different starting materials discussed previously. 
The first (Figure 28) comes from a synthesis employing DHA-DS as a starting material, 
and the last (Figure 29) comes from a synthesis utilizing glycerol as starting material. 
DMF signals are identifiable in both spectra. Based upon the structure of G-1,3-DS 
(Figure 16), the 1H-NMR spectrum for G-1,3-DS might be expected to be identical to that 
of DHA-DS, save for the addition of two signals, a singlet and a quintet, corresponding to 
the methine hydrogen and hydroxyl hydrogen now present at C-2. This is in fact, not the 
case, as can be readily observed in Figures 28 and 29. The region from 3.5 to 
approximately 4.0 ppm displays a more complicated splitting pattern. 
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Figure 28. 1H-NMR of G-1,3-DS in CDCl3 synthesized from DHA-DS. 
 
 
Figure 29. 1H-NMR of G-1,3-DS in CDCl3 synthesized from glycerol. 
 
 The reason for this splitting pattern can be explained by the spectrum in Figure 
30, which is an 1H-NMR spectrum of glycerol outlined to explain the splitting pattern. 
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The reduction of the carbonyl at C-2 transforms C-2 into a pro-chiral carbon, and thus the 
splitting of the methylene and methine protons is influenced by the now diastereotopic 
nature of the methylene protons, Ha (red) and Hb (blue) in Figure 30. The spectra of G-
1,3-DS in Figures 28 and 29 demonstrate this complex splitting as each hydrogen is 
“seen” individually, rather than when they were equivalent. Integration for the 1H-NMR 
spectra are not given, as the integration of peaks corresponding to each hydrogen signal 
belonging to the product of interest often produced fractional values, even when 
normalizing integrals for sample peaks. 
Samples were usually prepared from 10 to 20 mg of purified product reconstituted 
in approximately 1 mL of CDCl3. Product purity was corroborated by TLC, and the exact 
reason for the fractional integrals was difficult to pinpoint, but qualitatively, the spectra 
confirm the identity of each substance analyzed. 
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Figure 30. 1H-NMR of glycerol explaining the complex splitting observed over the 
region from ~3.3 to 4.5 ppm. (Image retrieved from: https://chemistry.stackexchange.com 
/questions/97786/h-nmr-equivalent-protons-and-coupling-of-glycerol) 
 
Esterification of G-1,3-DS with Arachidonic  
Acid to Form 2-AG-DS 
 Esterification of G-1,3-DS (the origin of which was from DHA-DS), with 
arachidonic acid was achieved with thionyl chloride, selected primarily for the ease of 
purification from by-products, SO2 and HCl, and amenability with the protecting group. 
Figure 31 gives the 1H-NMR for 0.2 mL of a 1 mg/mL solution of arachidonic acid in 
ethanol taken in approximately 1 mL of CDCl3. The signals for ethanol are readily 
discernible in the spectrum, theirs being the most intense. The strong triplet at 1.2 ppm 
corresponds to signals from the methyl group of ethanol, the quartet at 3.6 ppm 
corresponds to the methylene protons of ethanol, and the broad singlet at 3.7 ppm 
corresponds to the hydroxyl proton of the alcohol group of ethanol. The remaining peaks 
belong to arachidonic acid (excluding the chloroform signal at 7.3 ppm). Given that 
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arachidonic acid is a twenty-carbon polyunsaturated fatty acid, it is not surprising to find 
that the methyl and methylene regions of the spectrum are perfuse with signals from the 
hydrocarbon tail. A diagnostic multiplet at 5.3 ppm is produced by the methine protons of 
the four double bonds (R-CH2-CH=CH-CH2-R) at carbons 5, 6, 8, 9, 11, 12, 14, and 15 
of arachidonic acid. The complex signal at 2.8 ppm belongs to the methylene protons 
adjacent to the previously mentioned methine protons. A distinct quintet at 1.7 ppm 
belongs to the terminal methylene of the fatty acid tail (R-CH2-CH3) and the triplet at 0.8 
ppm belongs to the terminal methyl group of the tail. Finally, a triplet at 2.3 ppm 
corresponds to the methylene protons adjacent to the alpha carbon (the CH2 immediately 
adjacent to the carbonyl of arachidonic acid). Beyond this, peak assignment becomes 
difficult and speculative; the remaining multiplets at 1.2 and 2.1 ppm coming from the 
remaining methylene groups of the fatty acid tail.  
 
Figure 31. 1H-NMR of arachidonic acid (1 mg/mL solution in ethanol) in CDCl3. 
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 Figure 32 gives the 1H-NMR spectrum for 2-AG-DS. Successful esterification 
was validated by two methods in conjunction. First, qualitative TLC verified that the 
product isolated from the 2-AG-DS esterification step was pure, and second, the signals 
for G-1,3-DS (Figures 28 and 29) and the signals from arachidonic acid (Figure 31) are 
both present, as should be the case. Outside of minor signal shifts, the overlay of the 
spectra from G-1,3-DS and arachidonic acid (excluding solvent traces; DMF in Figures 
28 and 29 and ethanol in Figure 31) would produce a spectrum similar to the one present 
in Figure 32. The percent recovery of 2-AG-DS is given in Table 10. All the recoveries 
were lower than desired, the highest being 59%. Losses most likely occurred during the 
basic aqueous wash, which was intended to convert any free arachidonic acid to its ionic 
form (the pKa of arachidonic acid is 4.752 from https://pubchem.ncbi.nlm.nih.gov/ 
compound/231) thereby increasing hydrophilicity and allowing it to be washed away 
from the much less hydrophilic 2-AG-DS. It is likely that 2-AG-DS was more water 
soluble than thought, which is surprising given the structure of the protecting groups. The 
lower temperature at which the reaction was performed to prevent oxidation and 
degradation of the fatty acid could also contribute to lack of complete conversion, 
resulting in lower yield. The use of fatty acid chlorides in the preparation of glycerides is 
a well-established methodology (Bauer, 1946) and improvement in yield should be 
possible. 
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Figure 32. 1H-NMR spectrum of 2-AG-DS in CDCl3. 
 
Table 10 
Percent Recovery of 2-AG-DS 
Percent Yield  
53.7%  
59.1%  
45.8%  
Average 53 ± 7% 
  
Deprotection Analysis Complications 
 The final step in the synthesis of 2-AG involved the cleavage of the t-BDPSi ether 
protecting groups. As stated previously (see Table 5 in Chapter III), the first three 
deprotection methods were not analyzed with HPLC but were purified and analyzed by 
1H-NMR. Figure 33 shows the 1H-NMR spectrum from method A, Figure 34 shows the 
1H-NMR spectrum from method B, and Figure 35 shows the 1H-NMR spectrum from 
method C. Each 1H-NMR spectrum was consistent with 2-AG-DS, indicating that the 
first three methods employed for deprotection were not successful at 0 °C after 8 hr. 
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Minor differences do exist among the spectra, and are most likely attributable to the 
presence of impurities (more visible with the signal amplification necessary to resolve all 
peaks) owing to variances in purification and differences in the degree and accuracy of 
instrument shimming (explaining why some signals appear more diffuse than others). 
 
Figure 33. 1H-NMR of product in CDCl3 isolated from deprotection method A. 
 
 
Figure 34. 1H-NMR of product in CDCl3 isolated from deprotection method B. 
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Figure 35. 1H-NMR of product in CDCl3 isolated from deprotection method C. 
 
 This prompted interest in using HPLC to assess reaction progress, to allow a view 
across time, and to aid in assessing overall deprotection success independent of having to 
isolate the product. Since detecting free 2-AG is not practical with UV-Vis, the HPLC 
method adapted from Rouzer et al. (2002) was intended to monitor reaction progress by 
measuring the appearance of the primary by-product of deprotection, t-BDPSiF (Figure 
23), which will absorb at 274 nm. Method D (Table 5) was a repeat of method C, using a 
greater total molar concentration of acetic acid. Han and Razdan (1999) reported success 
using this method, which prompted the second attempt. Method E was borrowed from a 
cleavage method by Nikolaou and Webber (1986) that used a high concentration of 
hydrofluoric acid as a fluoride ion source. The conditions were of interest given the 
previously reported success of the cleavage of t-BDPSi ethers with these conditions. 
Unfortunately, there were significant issues with both the deprotection methods and the 
HPLC methodology. 
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 The key issue with the HPLC methodology can be seen in Figure 36, which 
shows a chromatogram of the 50 mg/mL standard solution of t-BDPSiF. The preparation 
of standards is given in Chapter III, but to give a brief generalized review, t-BDPSiF was 
generated from t-BDPSiCl by incubating 109 mg with 2.5 molar equivalents of fluoride 
ion (from TBAF) in THF which contained the anti-oxidant BHT. After quenching any 
remaining fluoride ion with MgCl2 and filtering the precipitate (MgF2), standard solutions 
were diluted from this 109 mg/mL stock and were chromatographed via HPLC in 20 µL 
aliquots. Each of the chromatograms had a similar qualitative appearance as the one in 
Figure 36, containing multiple signal peaks when only one was anticipated. At the time, it 
was presumed that the peak corresponding to t-BDPSiF would be apparent when peak 
areas were matched to sample concentrations; that a linear relationship would reveal the 
correct peak. This was an erroneous assumption, however, as several peaks produce a 
linear relationship when graphed versus the concentration of the t-BDPSiF standards. 
Some of the compounds contributing to the extraneous peaks are tetra-n-butyl ammonium 
cation (TBA+) and BHT, both of which absorb at 274 nm and would have a linear 
relationship when their peak areas were plotted against t-BDPSiF standard concentrations 
because they were diluted by the same factor. Acetic acid also weakly absorbs at 274 nm, 
and oxidized products of BHT could potentially be contributing signals as well. 
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Figure 36. HPLC chromatogram of 20 µL of 50 mg/mL t-BDPSiF. There are five 
distinctive peaks occurring at: 1.9 min, 5.0 min, 7.6 min, 8.9 min, and 10.1 min. 
 
 Sample aliquots taken from methods D and E analyzed by the same HPLC 
method also contained unknown peaks. Figure 37 shows the HPLC chromatogram of a 
sample aliquot from method E after 24 hr. The peak profile of the chromatogram aligns 
with the peak profile of the t-BDPSiF standard chromatogram from 0 to 10 min, which is 
confirmation that there is at least t-BDPSiF present in the sample; meaning deprotection 
had occurred. However, without a concrete way of assessing which peak belonged to t-
BDPSiF, drawing conclusions from the data set is very difficult. 
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Figure 37. Chromatogram of 24 hr aliquot from Method E. The sample was diluted 100-
fold prior to analysis (retention times for a sample calculation using this chromatogram 
are inset in the upper right corner) 
 
Another series of standards was planned in an attempt to resolve these peak 
identity issues, but several new challenges came along with further analysis. The goal 
was to obtain clean standards of TBAF, THF, t-BDPSiCl, and t-BDPSiF so that t-
BDPSiF elution time could be pinpointed by process of elimination and then correlated 
back to the chromatograms from method D and E, abrogating the necessity of running 
further deprotection trials. A stock solution of 103.7 mg/mL t-BDPSiF was prepared 
again as before, by incubating 103.7 mg t-BDPSiCl with 250 mg of TBAF for 24 hours. 
The only variation was the use of approximately 1.0 g of SiO2 granules instead of MgCl2 
to scavenge excess fluoride ion from solution prior to sample analysis.  
Instrument availability, and consideration for other work being performed at the 
time, required a change in the column used for the new trials, which was potentially a 
complicating factor. A reverse phase C18 Phenomenex column (4.6 mm x 150 mm; silica 
particle size 2.5-2.8 μm) was used instead of the Phenomenex Luna Omega Polar C18 
column previously used. It was hoped that the columns would not be so disparate in 
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resolution that the results would be unrelatable to the earlier samples. The following 
figures are from the same HPLC methodology using the reverse phase C18 Phenomenex 
column. Figure 38 displays a chromatogram of 20 µL of THF (containing BHT), Figure 
39 displays a chromatogram of 20 µL of a 10 mg/mL solution of TBAF in THF, Figure 
40 displays a chromatogram of 20 µL of pure t-BDPSiCl and Figure 41 displays the 
chromatogram for 20 µL of the stock solution of t-BDPSiF (concentration = 103.7 
mg/mL). Unfortunately, as before, each standard contained multiple peaks making peak 
assignment problematic. For instance, in Figure 39 (TBAF in THF) there are a host of 
overlapping peaks from approximately 1.0 to 3.0 min. These peaks were determined to be 
contaminates adhering to the column. Flushing with mobile phase at 1.5 mL/min for 
several hours did not help to alleviate this issue. Knowing the origin of these peaks 
(contaminates from previous analyses) allows them to be dismissed as candidates for 
TBAF, but there are several peaks outside of the 1.0 to 3.0 min range that need to be 
identified, specifically at 4.253 min, 4.981 min, 8.994 min, and a peak at approximately 
11 min. 
 
Figure 38. HPLC chromatogram of 20 μL of THF containing BHT. 
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Figure 39. HPLC chromatogram of 20 µL of approximately 10 mg/mL TBAF solution in 
THF. 
 
 
Figure 40. HPLC chromatogram of 20 μL of t-BDPSiCl. 
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Figure 41. HPLC chromatogram of 20 µL of 103.7 mg/mL t-BDPSiF in THF. 
 
Analysis of the standards to identity which of the peaks was t-BDPSiF was 
attempted, but it was still difficult to make this determination. For example, the standards 
prepared in THF concomitantly contained BHT, at a concentration between 0.025 to 
0.04% (m/v), which includes the chromatograms in Figures 38, 39, and 41. It should have 
been possible to use the chromatogram of THF (Figure 38) to pinpoint the elution time of 
BHT, which then might have helped to identify TBA+ in the chromatogram of TBAF 
(Figure 39), which would then allow both of those peaks to be eliminated from t-BDPSiF 
(Figure 41) giving the elution time for t-BDPSiF. This was not the case, however, as the 
peak profile of the chromatogram for THF contained unique peaks apart from the 
chromatograms of TBAF and t-BDPSiF (at 5.586 min), an unexpected result that 
confounded proper identification more than bringing clarity. Trying to work with the 
chromatograms to make other peak assignments was not possible either. In short, running 
further qualitative standards did not help in peak assignment.  
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Discussion of High Performance Liquid  
Chromatography Data 
 Although there were difficulties and ambiguities present in the HPLC data, there 
is still clearly the presence of t-BDPSiF in the sample aliquots from method E (see 
Figures 36 and 37) as established previously. Without a definitive peak assignment, 
assessing percent total deprotection of 2-AG-DS is impossible, but it is still possible to 
assess potential extent of deprotection by looking at each peak that might be t-BDPSiF 
and analyzing accordingly. This allows an establishment of a minimum/maximum for 
deprotection that occurred. 
 Figure 36 gives the chromatogram from the 50 mg/mL t-BDPSiF. There are five 
peaks of interest within this chromatogram, occurring at 1.9 min, 5.0 min, 7.6 min, 8.9 
min, and 10.1 min. Standard curves of the peak area vs concentration at each retention 
times were generated from the HLPC data from the standards (100 µg/mL, 1 mg/mL, 10 
mg/mL, 50 mg/mL, and 109 mg/mL). In sequence of increasing elution time, these 
graphs are given in Figures 42, 43, 44, 45, and 46. In each case, save for the standard 
curve for the peak at 1.9 min, the 109 mg/mL standard was discarded as an outlier, 
improving overall linearity for each graph. As can be seen in Figure 42, there is no linear 
relationship for the graph generated from the data set at 1.9 min, which is why this data 
set was disregarded for further analysis. Looking at Figures 43, 44, 45, and 46, there are 
clear linear trends of varying precision, as measured by the linear correlation coefficients 
(R2) provided for each under the trendline equations. 
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Figure 42. Standard curve for t-BDPSiF using 1.9 min peak 
 
 
 
Figure 43. Standard curve for t-BDPSiF using 5.0 min peak 
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Figure 44. Standard curve for t-BDPSiF using 7.6 min peak 
 
 
 
Figure 45. Standard curve for t-BDPSiF using 8.9 min peak 
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Figure 46. Standard curve for t-BDPSiF using 10.1 min peak 
 
To gauge potential deprotection, each of these standard curves were analyzed with 
the concomitant data from the chromatograms from deprotection methods D and E. 
Table 11 gives the results of this analysis. Referring to Figure 36, the chromatogram for 
the 50 mg/mL t-BDPSiF standard, the insert for the 10.1 min peak area is given in the 
upper right corner of the chromatogram. This chromatogram was generated from the     
24 hr aliquot from deprotection method E and was diluted 100-fold prior to analysis. A 
sample calculation for the generation of the values in Table 11 is given below for 
reference. 
Sample calculation for percent deprotection from Method E 
0.257 g 2-AG-DS into 5.140 mL = 50 mg/mL  
50 mg/mL x .02 mL ÷ 855.1 g/mol = 1.17 x 10-3 mol 
[(20784 x 100) – 1 x 106]/243604 = 4.43 mg/mL 
4.43 mg/mL x .02 mL ÷ 258.41 g/mol ÷ 2 = 1.72 x 10-4 mol 
y = 243604x + 1E+06
R² = 0.9562
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Percent deprotection = (1.72 x 10-4 mol ÷ 1.17 x 10-3 mol) x 100% = 14.6% 
Table 11 
Potential Percent Deprotection for Methods D and E 
Peak elution 5.0 min 7.6 min 8.9 min 10.1 min 
Method D (24 hr) < 0.3% < 0.3% N/A < 0.3% 
Method E (3 hr) < 0.3% < 0.3% < 0.3% < 0.3% 
Method E (24 hr) 15.2% < 0.3% N/A 14.6% 
 
 To explain the data in Table 11, there were three general outcomes from analysis. 
The first would be a negative result, which was interpreted as deprotection that fell below 
the lower limits of detection, which would mean deprotection less than 0.3%. The lowest 
t-BDPSiF standard analyzed was 100 µg/mL. Thus: 
0.1 mg/mL x 0.02 mL ÷ 258.41 g/mol ÷ 2 = 3.87 x 10-6 mol 
3.87 x 10-6 mol ÷ 1.17 x 10-3 mol = .003 = 0.3% 
The second was a result in excess of 100%, which is obviously not physically possible, 
and could indicate one of two errors. Either the peak being analyzed was simply not        
t-BDPSiF or the peak was a combination of compounds that absorb at 274 nm eluting 
together. These results were denoted with N/A. Finally, some results were considered 
valid, and are reported in the table accordingly. From this data set, it is possible to at least 
comment on the potential efficacy of each deprotection method. It seems that method D 
(6 mol equivalents of TBAF with 6 mol equivalent of acetic acid) is essentially non-
effective, while method E (10 mol equivalents of HF with 1 mol equivalent of pyridine) 
is sparingly effective, with a potential maximal deprotection of approximately 15% after 
24 hr. 
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2-Arachidonoyl Glycerol  
Recovery Outcomes 
 As mentioned previously in Chapter III, fractions were collected from the HPLC 
as they eluted at time points that corresponded to elution of 2-AG in the Rouzer et al. 
(2002) HPLC methodology (the basis for the method used). The goal was to determine 
where 2-AG was eluting in the hope that purification of 2-AG could be accomplished via 
HPLC by scaling up to a preparative column. Unfortunately, none of the fractions 
collected and screened via 1H-NMR showed any sign of 2-AG. Given the results in Table 
11, a simple explanation of this outcome might be that there was no 2-AG to collect, but 
some of the fractions collected did contain compounds that might have been a fatty acid 
by-product of the breakdown of 2-AG, indicating that the fluoride ion concentration 
might have been too strong. 
  Figure 47 shows an 1H-NMR from a fraction collected at 15.88 min from 
deprotection Method D. The HPLC method adapted for screening deprotection methods 
originally reported elution of 2-AG at 15 min and 1(3)-AG at 15.5 min (Rouzer et al., 
2002). Carbonyls will absorb in the UV-Vis spectrum with a maximum at 275 nm 
(Bayliss & McRae, 1954), so the presence of a peak here might have been indicative of 
either 2-AG or its isomer(s). The NMR signals had to be amplified considerably to be 
detected and fell exclusively between 0.0 to 3.2 ppm (save for the broad singlet at 4.7 
ppm from HOD, the deuterated solvent used for this 1H-NMR). Parts of the sample 
profile appear to match the fatty acid tail of 2-AG, with multiplets at 3.05 ppm and 1.55 
ppm, a triplet at 0.8 ppm, and a sextet at 1.25 ppm. However, the signature methine 
multiplet at 5.5 ppm is entirely absent, as well as many other characteristic signals for 2-
AG, which is suggestive that the sample is some by-product from the breakdown of 2-AG 
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or 2-AG-DS, although it could potentially be some entirely unrelated substance eluting 
from the column. With the limited data available, it is difficult to make definitive 
statements as to the identity of this compound, but the time at which it elutes and the 1H-
NMR profile suggests that it is some kind of hydrocarbon, but it is neither 2-AG-DS nor 
2-AG. Most fractions screened via 1H-NMR did not contain any detectable compounds, 
and the collection of analyzable material from each 20 µL fraction was so scant that 
analysis beyond NMR was not feasible. 
 
 
Figure 47. 1H-NMR of 15.88 min fraction from HPLC collected at 20 hours total run time 
from deprotection Method D. 
 
Single Flask Synthesis of 2-PG-DS  
in Dimethylformamide Using  
Thionyl Chloride 
 Running deprotection methods A through E exhausted all remaining available 2-
AG-DS. In the course of preparing new standards to resolve peak identity in the HPLC 
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chromatograms, the synthetic method for the preparation of 2-AG-DS was concomitantly 
reviewed. Up to this point, each intermediate from each synthetic step was isolated, 
purified, and characterized. This inevitably resulted in some minimal loss of product and 
time, as certain synthetic intermediates were more amenable to isolation and purification 
than others. Consequently, palmitic acid, a 16-carbon saturated fatty acid, was utilized in 
place of arachidonic acid during synthetic methodology development due to its cheaper 
price and suitability as a fatty acid substitute for arachidonic acid. The results from the 
deprotection methods screened up to this point demonstrated that amending previous 
methods that proved successful with deprotection of t-BDPSi ethers were seemingly not 
as successful as they were expected to be, and so returning to palmitic acid for the 
purposes of blanket screening more deprotection methods was immediately appealing. 
 It was established previously that DMF is the superior solvent for the formation of 
silyl ethers using the Corey methodology (Patschinski et al., 2014) at least in terms of 
reaction kinetics. Screening deprotection methods with a doubly silylated 2-palmitoyl 
glycerol compound would allow basic vetting of deprotection conditions that might be 
suitable for 2-AG-DS, but ultimately, given the unique stability constraints in using 
arachidonic acid, 2-AG-DS must still be screened separately in any conditions 
demonstrating successful deprotection (greater than 80% yield would be the goal). If 
there were a way to produce 2-AG-DS or the palmitic acid derivative (2-PG-DS) in a 
single reaction flask without the need for purification and transfer to a new reaction 
solvent in-between steps, it would be incredibly helpful for the purposes of screening and 
to ameliorate the need to isolate each intermediate and so lose potential product. 
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By using DMF as a solvent, however, there is a potential issue with the synthetic 
methodology. DMF itself contains a carbonyl, which should be reactive with thionyl 
chloride, potentially causing a cross reaction with the solvent, rendering this reagent and 
reaction pathway ineffective. However, this is not in fact the case, as the reaction of 
thionyl chloride with DMF generates a reactive chloroimium ion that then proceeds to 
react with free palmitic acid (or G-1,3-DS) to produce the fatty acid chloride that then 
proceeds to generate the ester. Figure 48 details this mechanism (Arrieta, Aizpurua, & 
Palomo, 1984). 
 
Figure 48. Mechanism for the generation of palmitoyl chloride with thionyl chloride. 
Note that the chloroinium ion generated may react with either palmitic acid or G-1,3-DS; 
whichever nucleophile it encounters first. 
 
 A reaction was set up to test the outcome for the synthesis of 2-PG-DS using 
glycerol as a starting material with the synthetic methodology described in Chapter III 
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but without isolating or purifying products in each step. The only alteration to the 
methodology in Chapter III was the performance of the esterification step at ambient 
temperature (21-23 °C) to hopefully improve yield. Figure 49 shows the 1H-NMR of the 
product isolated by liquid-liquid phase extraction of the DMF reaction mixture with 5 mL 
aliquots of hexane three times. The product matches the expected 1H-NMR profile of 2-
PG-DS. Signals in the 0 to 3 ppm range characteristic of the fatty acid tail are present, 
namely a 0.8 ppm triplet corresponding to the terminal methyl, a sextet at 1.6 ppm 
corresponding the adjacent methylene of this terminal methyl, and a triplet at 2.35 ppm 
corresponding to the methylene adjacent to the carbonyl. Further signals from the fatty 
acid tail methylenes exist as diffuse and overlapping multiplets between 1 and 2 ppm. 
The aromatic signals from the protecting group are clearly present in the corresponding 
region between 7 to 8 ppm. Finally, the telltale signals for glycerol occur in the region 
between 3.5 to 4.4 ppm and is shown on a zoomed in scale in the inset in Figure 49. This 
1H-NMR spectrum produced the sharpest and clearest signals of the splitting of the 
methine and methylene hydrogens from glycerol (Figure 30) to this point, demonstrating 
clearly that the generation of doubly silylated monoglycerols is achievable using DMF 
and thionyl chloride in tandem. The most welcome feature of the 1H-NMR is the fact that 
it is free of signals belonging to DMF, showing that purification, from the reaction 
solvent was complete. Table 12 gives the percent recovery for 2-PG-DS, showing a 
marginal improvement from before. 
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Figure 49. 1H-NMR of 2-PG-DS 
 
Table 12 
Percent Recovery of 2-PG-DS. 
Trial Percent Recovery 
1 60.7% 
2 77.1% 
Average 69 ± 12% 
 
Deprotection of 2-PG-DS 
 Three different trials were conducted to screen new deprotection conditions using 
the newly synthesized 2-PG-DS. The trials were modifications of the original Corey 
deprotection method (Corey & Veknateswarlu, 1972) utilizing TBAF in THF at higher 
concentrations than utilized previously. Concentrations of TBAF employed were 0.5, 1.0, 
and 2.0 M. Deprotection was carried out for 24 hr at 0 °C under inert conditions and 
sample aliquots were taken and analyzed using the same HPLC method and the C18 
Phenomenex column. Unfortunately, as before, deprotection results were difficult to 
interpret given the presence of multiple, unidentifiable peaks in the HPLC 
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chromatograms. The maximum amount of t-BDPSiF detected in-situ from HPLC analysis 
would place deprotection at 75.9%, but the chromatograms had ambiguities as before, 
and it is dubious whether that result is accurate. Figure 50 shows a graph of the peak area 
vs time for aliquots taken from the 1.0 M TBAF deprotection trial. The initial two data 
points on the graph seem to show a linear trend, a good sign that this might have been     
t-BDPSiF, however, the next two aliquots returned less total area, corresponding to less 
concentration, than the preceding reading. This was an unexpected result, but if accurate, 
it might imply that with increasing time t-BDPSiF was degrading. The final reading 
showed an increase in area once again, however, debunking that idea entirely and 
suggesting that either the standards were inaccurate or there were issues with the HPLC 
column or detector. 
 The presence of such trends in the data set generated from these deprotection 
trials is why they are excluded from this paper. As was stated previously, the difficulties 
that materialized in analyzing the deprotection methods via HPLC indicate that further 
work needs to be done to resolve these issues if HPLC is to be used further. 
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Figure 50. Peak area vs time for 2-PG-DS deprotection utilizing 1.0 M TBAF in THF. 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide  
Assay Results from CRL 1682 Cells Treated  
with Phytocannabinoid Extracts 
 Without the recovery of 2-AG, it was obviously not possible to screen cancer 
lines using the MTT assay with that compound; however, proof of the usefulness of this 
assay as a tool for measuring cancer cell culture response to cannabinoids can be seen in 
the following assays conducted using extracts from samples of marijuana containing the 
phytocannabinoids THC and CBD. 
 Figure 51 gives the MTT cell proliferation assay results for increasingly dilute 
treatments prepared from extracts from a marijuana sample with high THC content. The 
solutions were diluted an order of magnitude between each treatment well series. The 
cancer line being treated was a pancreatic cancer cell line, CRL 1682. The assay results 
show a proliferation pattern that is not uncommon for cannabinoids, where certain 
concentrations can enhance growth (as in the first two treatment concentrations) but then 
a concentration range, typically in the µM range, is reached where growth is completely 
abrogated (the next two treatment concentrations). Eventually, with continuing dilution, a 
growth enhancing effect returns (the final two treatment concentrations). Figure 52 shows 
an MTT cell proliferation assay of another extract of marijuana, a sample containing high 
amounts of THC and CBD. The results from this assay show a consistent anti-
proliferative effect for each increasingly dilute treatment (save for the undiluted extract), 
showcasing how combinatorial treatments utilizing multiple different cannabinoids with 
different affinities for the CB receptors can achieve treatment outcomes that are more 
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universally positive, and therefore, desirable. Results such as these clearly demonstrate 
why cannabinoids warrant investigation as anti-cancer agents. 
 
Figure 51. MTT cell proliferation assay of pancreatic cancer cells (CRL 1682) treated 
with high THC extract solutions. Extracts are ten-fold dilutions of a plant sample extract. 
 
 
Figure 52. MTT cell proliferation assay of pancreatic cancer cells (CRL 1682) treated 
with THC/CBD extract solutions 
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CHAPTER V 
CONCLUSIONS 
Current Status 
 The results of this research demonstrated that tert-butyldiphenylsilyl chloride is 
an appealing protecting group to generate protected 2-monoglycerols (in this case 2-AG-
DS or 2-PG-DS) from both DHA and glycerol, although not without draw backs. The 
discovery that the synthetic methodology could be carried out in a single reaction flask 
using the kinetically favored solvent, DMF, while still producing a good yield with 
SOCl2 is an appealing quality of this protecting group. Unfortunately, conditions 
employed to remove the protecting group seemed to be ineffective; however, given issues 
that were encountered with the methods employed to assess deprotection, this was not 
definitively established and bears further investigation. 
 The primary issue in assessing deprotection was acquiring pure standards to 
confirm peak identity of compounds absorbing at the wavelength of interest (274 nm). 
Without a way to pinpoint which peak belonged to which compound, interpreting the 
deprotection method effectiveness by HPLC becomes extremely difficult; which is why 
deprotection was given as a potential value. The additional confounding peaks in the 
standards have several potential origins. First, the HPLC columns used in screening 
standards and samples were additionally used for the analysis of other cannabinoid 
extracts and other laboratory samples. The removal agent employed in all deprotection 
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methods, fluoride ion, forms strong single bonds with Si, the Si-F bond dissociation 
energy being 540 kJ/mol compared to the bond dissociation energy of Si-C of 435 kJ/mol 
(https://labs.chem. ucsb.edu /zakarian/armen/11---bonddissociation energy.pdf), which is 
why it is widely employed to remove silyl ether protecting groups. This is also why the 
scavenging of free fluoride ion from sample aliquots with Mg2+ or silicon dioxide was 
vital before loading onto the column, as silica is the linker for the 18-carbon alkyl chain 
that constitutes the stationary phase for the reverse phase columns used in screening 
samples. It is possible that the sample depicted in Figure 48 (Chapter IV, page 82) that 
appeared to be a component of the fatty acid tail of 2-AG was in fact part of the C-18 
stationary phase that was liberated if fluoride ion attacked the silica column packing. 
Passage of injected samples through the column could also have liberated components 
adherent to the C-18 stationary phase through Van der Waals interactions, causing elution 
at sporadic times, which might explain the unexpected peak at 5.586 min in Figure 38. 
Although each sample was treated to ensure no free fluoride ion was allowed onto the 
column, it is unclear how even minute amounts introduced would impact column 
integrity and use, and this consideration was one reason further HPLC analysis was not 
pursued past the second series of standards. 
 It is my contention that deprotection was probably not as scant as what was 
detected. From the data for the deprotection trials conducted with 2-PG-DS, the 
maximum calculated deprotection was 75.9% (determined by blanket screening all 
pertinent peaks returned from aliquot analysis and treating as t-BDPSiF in an identical 
process detailed in Discussion of HPLC data on page 76), which is closer to the extent of 
deprotection reported previously (Nicolaou & Webber, 1986), but as discussed, given the 
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discrepancies in the data as a whole, it would be inappropriate to present this as a 
conclusion. The conditions used should have been more effective than detected. The 
removal conditions need to be able to be accurately assessed before attempting to screen 
further. 
 Return on yield prior to esterification was excellent. The esterification with 
thionyl chloride was less effective, showing improvement when conducted at ambient 
temperature. Increasing reaction temperature and adjusting reaction time could improve 
yield, while still avoiding unwanted side reactions, especially if carried out under inert 
conditions, as the oxidation of 2-AG and 2-AG-DS would be the greatest contributor to 
by-product generation and product loss at this stage. With these adjustments, the 
methodology could outperform other currently published procedures, and based upon the 
data obtained thus far, these adjustments should be readily implementable. 
 Based upon retrospective evaluation of the analytical methods and techniques 
employed for this research, there are several modifications that would potentially be 
fruitful. The first and most obvious, if the deprotection issues are in fact a reality, would 
be utilizing a different silyl ether protecting group for protecting DHA or glycerol. 
TMSCl (trimethyl silyl chloride) would be an interesting protecting group to evaluate, 
given its ease of removal in comparison to t-BDPSiCl (Greene & Wuts, 1999). It might 
be the case that TMSCl would not be amenable to use with SOCl2, but it is the most 
labile of the silyl ethers and its substitution would be a sensible next step in evaluation of 
these protecting groups with this methodology. 
Furthermore, qualitative TLC was consistently used as a tool to evaluate reaction 
completion and product purity, but in each case, a polar stationary phase was used. The 
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results of the HPLC analysis and 1H-NMR spectra indicate that products isolated might 
not have been pure. For instance, in Figures 28 and 29, the methyl and aromatic regions 
of these spectra contain additional unexpected peaks. The presence of these peaks 
indicates that there is likely a by-product from a previous step, namely the hydrated form 
of the protecting group, t-BDPSiOH, which is contributing the extraneous signals in those 
regions. Analysis of products isolated from intermediate synthetic steps via HPLC would 
be a more accurate, although time consuming, way of establishing product purity prior to 
1H-NMR analysis. 
Finally, qualitative TLC was frequently used to gauge reaction completion and 
product purity, but as established, the presence of extraneous peaks in 1H-NMR spectra 
indicate that the resolution was not sufficient to properly assess either. One improvement 
that could be made in this regard would be employing C-18 stationary phase for TLC and 
any column chromatography used to attempt to purify product. Given that HPLC analysis 
revealed the presence of multiple peaks in sample aliquots, it is possible that by-products 
carried from earlier reactions were contributing these additional signals, and since reverse 
phase HPLC columns were used, it is highly likely that the use of reverse phase in other 
analytical techniques employed would be helpful in resolving by-products or in the 
purification of product in intermediary steps. 
Future Work 
 A treatment modality that cannabinoids could be incorporated into with great 
therapeutic effect would be chemotherapy. Chemotherapeutic agents are typically known 
for their unwanted toxicological side effects (Cella & Cherin, 1988), but other practical 
difficulties involved with their use range from poor bioavailability, the development of 
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multiple drug resistances to these compounds, complications arising from lack of 
specificity for cancer targets, and simply poor therapeutic indices; many of these issues 
being directly conflated with the larger doses intended to increase efficacy against their 
target (Senapati, Mahanta, Kumar, & Maiti, 2018). One route being investigated to 
address these issues is the use of vehicles, such as lipid-based niosome (non-ionic 
surfactant-based vesicle) nano-carriers to facilitate the carry and delivery of hydrophilic 
drugs to tumor sites for targeted therapy (Naderinezhad, Amoabediny, & Haghiralsadat, 
2017). The association or sequestration of drugs with poor bioavailability with(in) lipid-
based carriers served as inspiration for a possible use of 2-AG as a hydrolyzable drug 
"sheath." The goal of this combination would be to improve the overall bioavailability of 
both compounds by chemically bonding them; eliminating hydrogen bond donors in 2-
AG, and adding more lipophilic character to small, poorly water-soluble 
chemotherapeutic agents. Figure 53 shows a model of this concept with 
aminoglutethimide (bracketed). 
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Figure 53. Aminoglutethimide drug "sheath" concept 
Aminoglutethimide is an aromatase inhibitor used to treat hormone-dependent 
breast cancer after first line treatments, such as tamoxifen, have proven ineffective 
(Patrick, 2013). The log P (where P is the partition coefficient; the ratio of the 
concentration of a substance across two immiscible solvents, in this case, concentration in 
1-octanol over concentration in water) of aminoglutethimide is 1.2 (https://pubchem 
.ncbi.nlm.nih.gov/compound/ aminoglutethimide), whereas the log P for 2-AG is 5.3 
(https://pubchem.ncbi.nlm. nih.gov/compound/2-arachidonoylglycerol), placing 2-AG in 
excess of Lipinski's recommended log P ≤ 5 (Patrick, 2013). However, bound together as 
in Figure 53, a hydrogen bond donor is eliminated, and the amalgamation will probably 
have a log P in between the two values of 1.2 and 5.3, making it closer to Lipinski’s 
recommendation. 
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This example is not perfect, as the combined molecular mass is in excess of the 
recommended 500 Da (combined MW = 620.79 g/mol) and aminoglutethimide is a 
perfectly serviceable drug on its own, and it is not clear that using it in this treatment 
method would be beneficial or even warranted. As a demonstration of a concept though, 
it is a good example to highlight a potential useful application of 2-AG. Such unions 
could boost overall efficacy through an entourage effect, once the molecule is hydrolyzed 
into its constituents. This could potentially give a more positive treatment outcome 
compared to the presentation of the drugs in isolation or even in synchrony. This is 
essentially identical to combinatorial therapy, but the kinetics of hydrolysis/dissociation 
might afford a different reactivity profile that would be worthwhile screening against cell 
culture. So long as the molecular weight of the compound being "sheathed" can be 
maintained in the neighborhood of 200 Da, and that the functional attachment to 2-AG 
does not require modifying either compound to the point of inactivity or toxicity, then 
there is no theoretical limit to what could be placed within the monoglyceride. 
Specificity for the desired target (the cancerous cells) is still an issue that is not 
resolved with this idea. However, given the data supporting the relatively non-toxic 
nature of cannabinoids to non-cancerous cells and their use as anti-emetic and pain-
relieving agents (Velasco et al., 2012), it might be the case that this treatment method 
would be more suited to use in conjunction with non-specific, anti-proliferative 
chemotherapy treatments. Utilized in this manner, the hydrolysis back into the 
constituents would theoretically produce effects that are more anti-proliferative while 
concomitantly counteracting at least the sensation of the unwanted physiological side 
effects (pain and nausea). 
98 
 
 
 
 There are obvious difficulties with this technique, however. The first would be 
obtaining a ready source of 2-AG that is activated at the terminal carbon of the fatty acid 
tail, such as 20-hydroxy-arachidonic acid, which to my knowledge represents a major 
hurdle already, this compound costing hundreds of dollars for microgram quantities 
(https://www.sigmaaldrich.com/catalog/product/sigma/h3023?lang=en&region=US). 
Furthermore, SAR studies to date have revealed the necessity for 3-4 double bonds in the 
fatty acid tail for proper activity at the CB receptors; fewer than that leads to inactivity 
(Mechoulam and Ben-Shabat,1999). Preliminary SAR studies looking at fatty acid chain 
substitutions, either of arachidonic acid, or complete substitution with a leukotriene or 
prostaglandin derivative, have shown lack of activity, save for one exception, 12(S)-
hydroxy-arachidonoyl ethanolamide, which will bind to CB1 (Mechoulam et al., 1998). 
These data reveal that finding a suitable cost-effective substitute might be challenging. 
Another route to increase 2-AG efficacy and potency would simply be 
modification of the compound itself, which was of primary interest and one of the major 
reasons direct synthesis was chosen. By examining published SAR data for model 
compounds, crystallography data for CB1, and giving priority to emerging drug design 
needs when making structural decisions, several interesting routes for modifying 2-AG 
exist that are worth exploring. As mentioned previously, SAR studies for 2-AG are not 
well published, but Mechoulam's group has purportedly forthcoming results indicating 
that 2-AG rudimentarily mirrors anandamide regarding SAR (Mechoulam et al., 1998). 
The 1(3) isomer of 2-AG was reported as binding to both CB receptors with similar 
potency as 2-AG, and the fatty acid derivatives 2-palmityoyl glycerol and 2-linoleoyl 
(18:29,12) glycerol showed no activity at either CB1 or CB2. This is in keeping with the 
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previous SAR findings where three to four double bonds were necessary for proper 
binding. Figure 54 gives the structure of anandamide and SAR information for this 
compound. 
The SAR information for anandamide can be used to help inform 2-AG 
modification, but beyond that, an interesting piece of information concerning the 
conformation that 2-AG assumes when binding to CB1 was given by Hua et al. (2016) in 
their crystallography study of the CB1 receptor, namely that 2-AG takes a "C-shaped" 
conformation (see Figure 5) in the pocket of CB1 and is predicted to bind similarly to that 
of THC. If the binding mode is similar to THC, it might also be possible to utilize SAR 
for THC to look for structural modifications for 2-AG to improve its efficacy. Prior to 
examining the SAR for THC, an attempt at demonstrating the overlay of these two 
compounds is presented in Figure 55. This figure does not necessarily reflect the actual 
conformation of 2-AG within the binding pocket, but simply gives a baseline upon which 
to form the following discussion. Without a rudimentary comparison, any SAR 
information concerning THC would be difficult to translate to 2-AG. 
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Figure 54. Anandamide SAR information. (Adapted from Mechoulam et al., 1998.) Each 
numbered SAR element (below) that corresponds to a specific part of the structure is 
numbered in the figure to facilitate discussion. 1) Double bonds must be ≥ 3-4 or activity 
is abrogated. 2) The unsubstituted amide is inactive. Mono-alkylation (substitution of the 
N-ethanolamide) up to a branched pentyl group exhibits significant activity, following the 
trend: C5H11 < CHMeCH2Me < n-C4H9 < t-C4H9 < CH3 < C2H5 < C(CH3)2, < n-C3H7. 3) 
N,N-dialkylation leads to loss of activity. 4) Hydroxylation preserves activity, but is 
lowered. 5) The methyl ether and phosphate are less active than the parent alcohol. 
Carbonyl derivatives are inactive. 6) In the n-3 series (in Mechoulam’s figure, n-x is the 
designation used to signal where the double bond series begins, so n-3 would be the third 
carbon starting from the terminal carbon of the fatty acid tail, similar to the Ω numbering 
system for fatty acids; 3-4 double bonds are necessary for activity but their sequence is 
flexible), derivatized ethanolamides are either inactive or less active than related 
compounds in the n-6 series. 7) Alkylation or di-alkylation of the α-carbon preserves 
binding; methylation or di-methylation potentiaties and increases activity. 8) Chiral 
centers on N-alkyl substituents lead to radically altered Ki. 9) Replacing the -OH with -F 
leads to a 10 fold increase in binding to CB1. 10) Conjugation of the double bonds leads 
to reduced activity. 11) Branching of the fatty acid tail enhances binding. 
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Figure 55. Overlay of 2-AG (red) with THC (black), attempting to show potential 
similarity in binding 
 
 Figure 56 is a diagram of THC outlined for discussion of SAR elements for this 
compound. Although numerous major pharmacophores are present within THC, one of 
the main moieties responsible for variation in receptor binding parameters is the C3 side 
chain. The chain has a minimum length requirement of three carbons and was 
characterized as being ideal at 5-8 carbons (Bow and Rimoldi, 2016). 
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Figure 56. Diagram of THC outlining pertinent pharmacophore moieties 
Table 13 gives the relationship between chain length and respective Ki for THC 
modified at C3 for CB1. This relationship coincides nicely with the overlay presented in 
Figure 56, in the sense that it is easy to mentally add additional carbons at C3 for THC 
and see how they could conform to the backbone of the fatty acid tail of 2-AG. 
Furthermore, SAR studies examining modifications of the chain at C3 show that 
dimethylation of C'1 (the first carbon of the chain) and a total of eight carbons in the 
chain length (1,1-dimethyloctane) gives a Ki of 0.9 nM, a full order of magnitude below 
that of the ideal chain length in Table 13. Further SAR on C3 showed that the 
introduction of alkyne functional groups (rigidity) have varying degrees of effects on Ki 
constants for THC, usually being positive in nature. These data are indicative of the 
necessity of rigidity within the fatty acid linked to glycerol for appropriate binding. 
Studies looking at restriction of the orientation of the chain itself have shown that when 
the chain is locked into a downward conformation (away from the bulk of the molecule, 
specifically the C1 phenol), it is the more kinetically favored orientation (Bow and 
Rimoldi, 2016). 
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Table 13 
Relationship Between C3 Chain Length of THC and CB1 Affinity as Measured through 
Ki. (Adapted from Bow and Rimoldi, 2016). 
Chain Length Ki (nM) 
1 n/a 
2 n/a 
3 75.4 
4 65 ± 13 
6 41 ± 3.8 
7 22 ± 3.9 
8 8.5 ± 1.4 
  
Modification of the C1 phenol has the general effect of increasing CB2 specificity, 
both with removal or methylation. Modification of the phenol beyond methylation tends 
to abrogate activity at both receptors, showing the sensitivity of the receptor to this group. 
Modification at the C9-C11 group does not confer variable selectivity but impacts 
receptor affinity. Specifically, the replacement of C9-11 with a carbonyl confers an order 
of magnitude increase in Ki for CB1 and CB2, and the THC derivative generated is 
identical to Cesamet® (generic nabilone) which is a medication prescribed to attenuate 
decreased appetite and the secondary wasting associated with chemotherapy (Bow and 
Rimoldi, 2016). 
 Based upon the SAR for THC and the fact that substitution of the hydroxyl group 
in anandamide increases CB1 affinity, the following permutations of 2-AG are anticipated 
to be worth investigating for their increased affinity for CB1 (Figure 57). Increased 
receptor affinity for a drug class is desirable if steady state concentrations are difficult to 
reach a therapeutic concentration but is generally appealing for the ability to minimize 
dosing requirements or if dose directly scales with therapeutic efficacy. It is appealing to 
modify 2-AG in this way given its transient nature in physiological conditions; increased 
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efficacy could potentially render a compound with physiologically beneficial effects 
which is essentially benign when metabolized/hydrolyzed. Glycerol's ultimate 
physiological fate is connected with benign intersections with carbohydrate/lipid 
metabolism, and arachidonic acid has multiple biological fates, but most likely would be 
sequestered into a biological membrane, outside of situations where it would be 
incorporated into an alternative metabolic pathway (such as COX-1/2-mediated 
prostaglandin synthesis). 
 
Figure 57. Suggested modification of 2-AG. Three possible permutations are of interest, 
with the distinction between the three being substitution at X, with the variable 
substitutions being: 1) -H, 2) -OH, 3) -CH3.  
 
 The goal with the proposed modification to 2-AG is two-fold. First, from the SAR 
discussed previously, there is the potential to increase CB1 affinity by expanding the 
molecule into the shallow pocket filled by arm 3 of AM6538 described in Figure 9. This 
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pocket is what N-alkyl extensions on anandamide occupy (Hua et al., 2016) and must be 
host to a cationic amino acid residue at its basin, as evidenced by the order of magnitude 
increase in CB1 affinity when substituting an electronegative fluorine or chlorine atom for 
the -OH in anandamide. The second is to preserve the overall water solubility of 2-AG. 
Figure 57 shows a series of proposed modifications to 2-AG, seeking to meet both these 
goals. The addition of the substituted fluorobenzene at the 1 position of the glycerol is 
meant to fill into arm 3, with the hope that the steric bulk of the addition will favor 
orientation of the fatty acid tail downward, the more kinetically favored orientation (Hua 
et al., 2016). The substitutions at X (given in Figure 58) are intended to moderate binding 
affinity and solubility, and screening the substitutions looking at these two variables 
would be the first step in judging these 2-AG permutations. Based upon the SAR 
discussed previously, the compound should have a pronounced increase in affinity for 
CB1, and the substitutions at X should serve to allow tuning of this affinity. 
Exploring this concept experimentally brings its own challenges. In no particular 
order: 1) addition of the fluorobenzene moiety must be accomplished at C1, not C3, and 
so setting up the nucleophilic substitution with 1-fluoro-4-iodobenzene would require 
"feathering" the reaction conditions so as to generate a single substitution and then 
subsequent isolation and purification of the desired isomer, 2) the new compound now 
possesses a chiral center, the effects of which on receptor binding were reported as 
minimal (Bow and Rimoldi, 2016); however, for pharmacological development, each 
isomer must be isolated and screened individually, 3) the introduction of a halogenated 
benzene introduces new issues in overall compound toxicity, since halogenated benzene 
compounds are implicated in numerous pathologies (Environmental Protection Agency, 
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2006), and assessing receptor affinity for this compound, and any other 2-AG derivative 
of interest, will face identical challenges as those encountered by previous studies 
(detailed in Chapter II). 
 None of these issues are insurmountable; however, in combination they pose a 
challenge requiring ingenuity to approach. With the publication of a crystal structure for 
CB1, using mathematical models to predict an idealized, stable agonist is a clearly 
favored path forward, and adapting such models to inform structural modification of 2-
AG to improve CB1 affinity is a rational next step. Regardless, the only true test is to 
synthesize each compound and screen with the appropriate battery of tests. 
Summary 
 The total content of this thesis has covered a broad range of topics from the socio-
cultural impediments to the study and use of the psycho-active constituents of C. sativa, 
to the discovery and elucidation of a novel cannabinoid receptor system and the 
associated endogenous ligands, to the integration and effects of the cannabinoid receptor 
system in the cellular cycle, and finally, the implications of these effects in the pursuit of 
using cannabinoids in cancer treatment modalities. The purpose of presenting this breadth 
of information was to give the appropriate context for the reasons for undertaking this 
project to begin with, and why the pursuit of an improved synthetic route for 2-
arachidonoyl glycerol is a desirable goal. The goal of synthesizing 2-AG is a stepping 
stone on a path that hopefully leads to methods by which cannabinoids can be 
incorporated into cancer treatment modalities to improve existing treatment 
methodologies or even generate completely novel treatment methods. Doing this requires 
a view that encompasses not just the chemical, biological, and physiological background, 
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but also the sociological and legal impediments for bringing these compounds into 
pharmacological treatment and distribution systems. 
 The breadth of the task and challenges involved can be daunting. Only further 
time and research will tell if cannabinoids can be integrated into new and successful 
treatment modalities, but if the current state of knowledge is anything to go by, there are 
many reasons to hope. There is also much more work to be done. 
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